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CHAPTER I 
 
INTRODUCTION 
The presence of bacteria in the circulatory blood initiates a cascade of local and systemic 
regulatory mechanisms that often result in sepsis1. Sepsis, defined as a life-threatening organ 
dysfunction caused by a dysregulated host response to infection, afflicts over one million 
Americans annually and has an associated mortality rate ranging from 25-50%2,3. Sepsis is the 
leading cause of death in the critically ill in the United States, costing the US over $20 billion in 
treatment annually2,3. These statistics clearly define a tremendous clinical need for improved 
therapeutic strategies to better address sepsis and sepsis progression.  
Acinetobacter baumannii, a Gram-negative coccobacillus with a multi-drug resistant (MDR) 
phenotype, is a leading cause of sepsis worldwide4,5. A. baumannii is widely distributed in nature 
and has few nutritional requirements for growth6. The organism is able to thrive at various 
temperatures and pH conditions, while utilizing a variety of carbon and energy sources7,8. These 
properties help explain the resilient fitness of A. baumannii, contributing to its rapid transmission, 
and aid in our understanding as to why this bacterium continues to persist even in harsh 
environments. A. baumannii is not only characterized by robustness, but this bacterium also has 
an intrinsic resistance to many antibiotics, contributing to its MDR phenotype9. These 
characteristics have led the CDC to classify A. baumannii as a ‘Serious Threat’ to the United 
States, warning that the threat will continue to worsen if new treatment and prevention therapies 
are not developed10.   
A. baumannii rates of infection are significantly increasing due to the expanding incidence 
of MDR A. baumannii species11. As humans continue to inadvertently accelerate the evolution of 
bacterial resistance through over-use of antibiotics, the major problem of MDR will grow in scope 
and impact. Immunosuppression and neutropenia are significant risk factors associated with 
development of A. baumannii induced sepsis12. If left untreated or inappropriately treated, 
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progression of sepsis can lead to widespread inflammation, blood clotting, multiple organ failure, 
pneumonia, septic shock, and death6.  
The lack of new antibiotics in the developmental pipeline, combined with increasing 
numbers of elderly and immunocompromised populations, suggests that the incidence of A. 
baumannii-associated sepsis will continue to pose as a significant global health problem13. A 
common treatment for A. baumannii-associated sepsis is empiric, broad-spectrum antibiotic 
therapy. Unfortunately, high dose antibiotic administration can result in serious side effects, 
including significant renal and neurological toxicity14. The increasing incidence of A. baumannii-
associated infection combined with the lack of effective and safe antibiotics is leading us into the 
post-antibiotic era. New treatment methods for sepsis must be developed and utilized to counter 
antibiotic ineffectiveness and overuse.  
Various research groups have attempted to circumvent the limitations of monotherapy 
antibiotic treatment by using synergistic antibiotic combination therapies against A. baumannii 
species. Novel combinations of antibiotics have proven to be effective at eradicating A. baumannii 
infection15–17. However, multi-drug therapies promote the development of antibiotic resistance 
through the bacterium production of drug-inactivating enzymes, efflux pumps, and target-site or 
outer membrane modifications18. Pan-drug resistant A. baumannii strains have already 
emerged19,20.  
Progression from sepsis to severe sepsis or septic shock results partially from an initial 
failure to effectively eradicate infection. Bacterial cells and endotoxins propagate from the primary 
site of infection to distal organ sites through the bloodstream, overwhelming the immune system 
and causing a dysregulated host response to infection.   Alternative treatment methods (e.g. fluid 
resuscitation, anti-thrombosis therapy, removal of inflammatory mediators, and organ support) do 
not address the root cause of sepsis - the persistence of pathogens that continuously release 
pathogen-associated toxins into the bloodstream21. 
All major antimicrobial resistance mechanisms known to occur in bacteria are employed 
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by A. baumannii to escape antibiotic-induced death22. This has led researchers to work towards 
developing therapies that treat the root cause of sepsis and are not reliant on antibiotic-induced 
bacterial cell death. A number of approaches, founded on separation biophysics, have been 
demonstrated to isolate bacteria from simple fluids.  For example, bacteria-targeting magnetic 
nanoparticles (MNPs) have been designed to bind bacteria, which can then be separated from 
fluid with up to 50% efficiency by applying external magnetic fields23–25. It has been reported by 
Singh et al. that surface-functionalized MNPs can be used for capture and magnetic extraction of 
Escherichia coli from saline solution24. Also, Kang et al. have successfully employed genetically 
engineered human opsonin functionalized MNPs to capture and remove Staphylococcus aureus 
and Escherichia coli from fluid25. Mathematical modeling, however, suggests that effective binding 
to bacteria in whole blood at physiologically relevant flow rates requires MNP diameters of less 
than 50 nm, which is too small to isolate even for the most advanced magnetic separation 
systems26,27. Therefore, more work must be done in order to develop other bacteria separation 
strategies, including bacterial hemofiltration. 
Hemoperfusion columns designed to remove endotoxin (lipopolysaccharide) and 
cytokines from the blood have been developed for the treatment of sepsis28,29. However, these 
columns do not remove bacteria and have not been approved for use in the US, citing the lack of 
effectiveness and clogging. Therefore, an improved technology must be developed to treat the 
root cause of sepsis through direct removal of pathogens and endotoxins, overcoming the surface 
area limitations imposed by membrane-based column filters and eliminating the risk of clogging.  
Recently, microfluidic cross-flow filtration methods have been used to sequester bacteria 
from whole blood. Raub et al. have developed a size-exclusion based microfluidic device for this 
purpose30. The implementation of size-exclusion and margination-based cross-flow channels in a 
microfluidic device allowed for 30% separation of bacteria from red blood cells using flow rates 
up to 100 μL/min.  
Inertial lift and Dean forces have also been used in more complex microscale spiral or 
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double spiral systems to focus particles into multiple, size-dependent equilibrium positions within 
the channel cross section, leading to distinct microparticle separation31,32. These types of inertial-
based microfluidic devices have been shown to separate 5 μm sized particles from 15 μm sized 
particles with a 95% separation efficiency (Fig 1.1)32. Appropriate alteration of channel geometry 
and the ratio of inertial lift force to Dean force can result in particle stream migration near the walls 
of a double spiral microchannel. By taking advantage of the large inertial lift forces experienced 
by particles in high aspect ratio spiral channels, particles as small as 590 nm in diameter have 
been shown to migrate into particle streamlines near the channel walls, away from the channel 
center (Fig 1.2)33.   
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Figure 1.1. Superimposed fluorescent images taken within the outlet of a double spiral 
microfluidic channel show the separation of 5 µm (green) and 15 µm (red) particles at various flow 
rates32. 
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Figure 1.2. a, Simulation results indicating the 590 nm particle distribution across the channel 
width in the spiral channel. b, Experimental result showing the 590 nm particle distribution 
(fluorescent stream) across the channel width at the outlet33. 
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These results demonstrating the separation of micron-sized particles from flowing fluid 
using spiral microfluidic systems are promising and have the potential to be further altered and 
scaled for capture and removal of bacteria from fluid, thereby aiding in the treatment of bacterial 
sepsis. Bacteria are heterogeneous in size and shape, unlike the homogenous spherical particles 
used in Figures 1.1 and 1.2. Therefore, the translation of the previous work to bacteria is nontrivial.  
 
Objectives 
The central hypothesis of my dissertation is that a model-based fluidic platform can be 
used for inertial focusing and capture of Acinetobacter baumannii, including colistin-resistant 
variants. Furthermore, I hypothesize that the proposed approach will remove A. baumannii from 
whole blood, providing a new paradigm for the treatment of sepsis. This approach addresses the 
unmet need for improved bacterial eradication through extracorporeal blood cleansing, which, in 
the absence of effective antibiotic treatment, represents the most powerful and adaptive system 
for blood-borne bacterial elimination. Therefore, the objectives of this work are to (1) fabricate a 
ligand designed to capture and bind A. baumannii, including colistin-resistant variants, (2) develop 
a computational model that enables prediction of A. baumannii clearance characteristics needed 
for successful removal of bacteria from circulation, and (3) design a mathematical model-based 
fluidic platform functionalized with the A. baumannii-targeting ligand for capture of the pathogen 
from fluid. 
 
Specific Aims 
Specific Aim 1: A ligand designed for the capture of Acinetobacter baumannii from fluid will be 
synthesized. Assessment of A. baumannii capture using the designed ligand will be characterized. 
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Specific Aim 2: A mathematical model describing the kinetics and distribution of A. baumannii 
pathogenesis will be developed. This model will be used to predict A. baumannii clearance 
requirements for the treatment of sepsis. 
 
Specific Aim 3: Modeling predictions will be incorporated to design and fabricate an inertial-
based fluidic platform decorated with an A. baumannii-targeting ligand for the separation and 
capture of A. baumannii from flowing fluid. Separation and capture of A. baumannii from flowing 
fluid through ligand interactions will be characterized. 
 
Background and Significance 
This research addresses the need for a better understanding of the feasibility of bacterial 
separation from flowing fluid. Bacterial separation techniques have been developed for the 
treatment of sepsis, however, feasibility of these techniques remains unknown. Therefore, this 
work is aimed towards developing a bacterial pathogenesis model to inform bacterial separation 
needs, which will then be used to build and test a bacterial separation device. Sepsis afflicts 
millions of people globally each year and is ranked among the top seven causes of death in 
Europe and North America34–36. Development and progression of sepsis is often a result of 
immunosuppression, previous antibiotic therapy, or previous sepsis, each of which are 
independently related37. Acinetobacter baumannii, a Gram-negative coccobacillus, is a 
particularly formidable cause of sepsis and fatal bacterial toxemia because it is both difficult to 
control and treat37. This microorganism can persist in the harshest environments and colonize a 
wide range of human and environmental reservoirs37,38. The great resilience and genomic 
plasticity of A. baumannii, combined with overuse of antimicrobials, has promoted the evolution 
of multi-drug resistant (MDR) A. baumannii along with the acquisition of novel virulence 
characteristics39. The transformation of A. baumannii into an antimicrobial-evading pathogen has 
severely restricted the therapeutic options available for infected patients, and has increased 
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mortality rates40,41. The continued stagnation of antibiotic development, combined with the large 
number of negative side effects associated with antibiotic administration, has led to the need for 
development of new treatment strategies for A. baumannii sepsis. This work details the 
development of a microfluidic device-based approach that addresses these key issues and 
enables selective capture and eradication of A. baumannii from flowing fluid.  
Colistin, a polycationic molecule, selectively interacts both electrostatically and 
hydrophobically with the negatively charged lipid A component of bacterial lipopolysaccharide 
(LPS), the major outer membrane component of Gram-negative bacteria42,43. Although colistin-
functionalized nanoparticles are particularly useful for the capture of A. baumannii in fluid, 
extraction of nanoparticle-bound bacteria is a nontrivial limitation of this technology. To circumvent 
this obstacle, a model-based microfluidic channel decorated with a colistin ligand was developed, 
which was used to capture A. baumannii from fluid. The microchannel dimensions were designed 
in such a way as to leverage inertial lift forces to focus the bacteria near the colistin-functionalized 
channel walls, thereby allowing continuous capture and removal of A. baumannii from the flowing 
fluid. This innovative bacterial separation device not only enables the removal of A. baumannii 
from fluid, but also removes endotoxin and other Gram-negative bacteria species from circulating 
fluids. This work will inform the design and feasibility of bacterial separation devices, which could 
have the capacity to aid in the treatment of sepsis. The breakthrough concept of this work is that 
this inertial-based fluidic platform can separate and immobilize bacteria from continuously flowing 
whole blood, avoiding obstacles to translation that limit blood purification therapies that utilize 
membrane-based filters for removal of inflammatory mediators and other toxins. Advancement of 
this work may improve sepsis-associated outcomes by treating sepsis rapidly at the source and 
potentially decrease the current threat of the ‘post-antibiotic era’ through effective treatment of 
multi-drug resistant pathogens. Mechanically removing bacteria and endotoxins breaks the 
current paradigm of sepsis therapy that is focused on applying antibiotics following 
bacterial culture and identification. 	
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CHAPTER II 
 
COLISTIN LIGAND FOR THE RAPID CAPTURE OF BACTERIA 
Gold nanoparticles (AuNPs) were functionalized for rapid binding of Acinetobacter 
baumannii (A. baumannii), a Gram-negative bacterium. AuNPs were functionalized with colistin 
(Col), a polycationic antibiotic, using a two-step self-assembly process, in which 
heterobifunctional polyethylene glycol (PEG) was used as a linker. Colistin was successfully 
conjugated to the AuNPs (Col-PEG-AuNP), as validated by dynamic light scattering (DLS) and 
proton nuclear magnetic resonance (H1 NMR). High angle annular dark field scanning 
transmission electron microscopy (HAADF-STEM) images, acquired simultaneously with x-ray 
energy dispersive spectroscopy (EDS) data, confirmed binding of Col-PEG-AuNPs to the cell 
envelope of A. baumannii. Results generated from a rapid binding assay indicated that Col-PEG-
AuNP complexation with A. baumannii occurred rapidly and reached half-maximum saturation in 
approximately 7 minutes, on average, for all A. baumannii strains evaluated. Quantitative 
measurement of the kinetics of Col-PEG-AuNP binding to A. baumannii is essential to inform the 
design of colistin-functionalized magnetic nanoparticles for magnetic separation of nanoparticle-
bound A. baumannii. Results from this chapter will fulfill Specific Aim 1 of my dissertation.  
 
Introduction 
Acinetobacter baumannii is commonly found in soil, water, mucous membranes, 
vegetables, and on human skin1. Individuals with a compromised immune system, diabetes, or 
wounds can suffer from life-threatening infections resultant from A. baumannii. Infections caused 
by A. baumannii can lead to widespread inflammation, blood clotting, multiple organ failure, 
pneumonia, septic shock, and death6. A. baumannii is responsible for 2% to 10% of Gram-
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negative bacterial infections worldwide and has an associated mortality rate reaching up to 
60%41,44,45.  
The spread of A. baumannii occurs via human contact and through contact with 
contaminated food, soil, water, and hospital equipment46.  A. baumannii has been detected in 
freshwater ecosystems, sewage, wastewater, drinking water, and groundwater supplies46,47. 
Infections resultant from A. baumannii and other Gram-negative bacteria can be transmitted by 
contaminated drinking water48. Various adsorption columns have been developed for the removal 
of bacteria from fluid49–51. Unfortunately, these devices have drawbacks due to slow, diffusion-
limited operation and surface sites, which decrease the adsorption capacity of the adsorbent. 
Separation of adsorbents from bulk medium can be complex. Thus, the development of 
adsorbents with higher adsorptive capacity, low diffusion resistance, and fast separation is of 
great importance in practical engineering applications.  
Recently, alternative approaches have been sought to address the shortcomings of 
current treatments for various bacterial contaminations and infections. In particular, bacteria-
targeting magnetic nanoparticles (MNPs) have been developed for the separation of MNP-bound 
bacteria from wastewater or blood using external magnetic fields24,52. Nanoparticles have a high 
surface area to volume ratio, which enables high adsorption efficiency. Singh et al. have reported 
that surface-engineered MNPs allow for successful capture and extraction of Escherichia coli from 
PBS24. Also, Kang et al. have reported that genetically engineered human opsonin functionalized 
MNPs can be used to successfully bind and extract Staphylococcus aureus or Escherichia coli 
from biological fluid25.  Unfortunately, very few nanoparticles have been shown to bind A. 
baumannii.  Also, many of the nanoparticles developed for bacterial capture are functionalized 
with genetically engineered, synthetic, or biomacromolecular ligands. Such surface 
functionalization may pose special challenges in achieving the Food and Drug Administration 
(FDA) approval required for many important applications.  Furthermore, very few reports indicate 
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bacterial capture in less than 1 hour. This is a notable unmet need because rapid extraction of 
bacteria is essential in order to allow effective decision-making in assessing potential pathogen 
contamination and to minimize risk of infection.  
We have developed a novel colistin (Col) functionalized gold nanoparticle (AuNP) that is 
designed to rapidly capture A. baumannii. Colistin, a naturally occurring cationic decapeptide 
isolated from Paenibacillus polymyxa var. colistinus53, is a potent broad-spectrum antimicrobial 
that was first used in the 1950s. The cationic colistin molecule and the negatively charged lipid A 
component of bacterial lipopolysaccharide (LPS) interact both electrostatically and 
hydrophobically42,43, presumably allowing for colistin functionalized gold nanoparticle capture of 
A. baumannii. The amount of colistin conjugated to the AuNP surface was carefully designed to 
improve A. baumannii binding kinetics.  Additional thiolated polyethylene glycol (PEG), lacking 
colistin, was used to passivate AuNP sites left unoccupied by colistin groups, thereby minimizing 
nonspecific interactions.  
Utilizing colistin as a targeting ligand presents many advantages over synthetic, 
genetically engineered, or biomacromolecular ligands that have been used in this context24,25,52. 
One advantage is that colistin is a readily available, approved antibiotic that has been used in the 
clinical setting for decades. This design simplifies development and facilitates regulatory 
considerations relative to the use of genetically engineered or new biomacromolecular ligands. 
The effects of colistin surface presentation on the colistin functionalized gold nanoparticles were 
examined, and the results of in vitro binding kinetic experiments with A. baumannii are presented. 
 
Materials and Methods 
Materials 
All materials were obtained from Sigma-Aldrich (St Louis, MO, USA) and used as received 
unless otherwise noted. 
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Methods 
Synthesis of colistin functionalized gold nanoparticles (Col-PEG-AuNPs) 
Col-PEG-AuNPs were prepared using a multistep approach 
 (i). Conjugating Colistin to NHS-PEG3400-OPSS tethers. Colistin sulfate (Sigma-Aldrich, 
Batch # ALBN5158V) was suspended in 100 mM sodium bicarbonate (NaHCO3) (Sigma-Aldrich, 
Lot # 017K0165) (pH 8.5) at a concentration of 0.29 mg/mL.  NHS-PEG3400-OPSS (succinimidyl 
ester-polyethylene glycol-ortho-pyridyl disulfide, Laysan Bio, Inc., Arab, AL, USA) was prepared 
in 100 mM NaHCO3 at a concentration of 3.19 mg/mL. 900 μL of NHS-PEG3400-OPSS solution 
was added in drop-wise fashion to 9 mL of colistin solution. The solution was vortexed for 10 
seconds and then allowed to react at 4°C for 2 h.  
(ii). Attachment of Colistin-PEG3400-OPSS onto AuNPs. 1.425 mL of Colistin-PEG3400-
OPSS from step (i) and an additional 75 μL of 100 mM NaHCO3 solution were added to 15 mL of 
20 nm gold nanoparticle (AuNP) suspension (Ted Pella Inc., Redding, CA, USA, Lot # 012126). 
The solution was incubated at 21°C for 1 h. 
(iii). Passivation of Col-PEG-AuNPs with HS-mPEG2000. 109 μM HS-mPEG2000 (thiol-
polyethylene glycol, Laysan Bio, Inc., Lot # 136-102) was prepared in distilled water. 1.5 mL of 
109 μM HS-mPEG2000 solution was added to the Col-PEG-AuNPs resultant from step (ii), and 
then incubated at 21°C for 1 h. Following incubation, the functionalized nanoparticles were 
centrifuged at 8,000g (21°C) for 30 minutes. The supernatant was decanted and particles were 
resuspended in 70% ethanol. The solution was stored at 4°C for 24 h.  
Synthesis of polyethylene glycol-functionalized gold nanoparticles (PEG-AuNPs)  
PEG-AuNPs were prepared in three steps 
(i). Dilution of NHS-PEG3400-OPSS. NHS-PEG3400-OPSS was prepared in 100 mM 
NaHCO3 (pH 8.5) at a concentration of 3.19 mg/mL. 900 μL of NHS-PEG3400-OPSS solution was 
added in drop-wise fashion to 9 mL of 100 mM NaHCO3 solution. The solution was vortexed for 
10 seconds and then stored at 4°C for 2 h. 
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(ii). Attachment of NHS-PEG3400-OPSS onto AuNPs. 1.425 mL of NHS-PEG3400-OPSS 
solution from step (i) and an additional 75 μL of 100 mM NaHCO3 solution were added to 15 mL 
of 20 nm AuNP suspension. The solution was incubated at 21°C for 1 h. 
(iii). Passivation of PEG-AuNPs with HS-mPEG2000. 109 μM HS-mPEG2000 was prepared 
in distilled water. 1.5 mL of 109 μM HS-mPEG2000 solution was added to the PEG-AuNPs resultant 
from step (ii), and then incubated at 21°C for 1 h. Following incubation, the functionalized 
nanoparticles were centrifuged at 8,000g (21°C) for 30 minutes. The supernatant was decanted 
and particles were resuspended in 70% ethanol. The solution was stored at 4°C for 24 h.  
Physical characterization of Col-PEG-AuNPs and PEG-AuNPs 
Unconjugated AuNPs, Col-PEG-AuNPs, and PEG-AuNPs were centrifuged at 8,000g 
(21°C) for 30 minutes. The supernatant was decanted and particles were resuspended in 
nanopure water at a NP concentration of 0.5 mM. Droplets of diluted, aqueous NP suspensions 
were deposited on carbon film-backed copper grids (Ted Pella Inc., 400 mesh Cu, Lot # 250315) 
and blotted dry. Samples were left to dry for 2 h at 25°C prior to transmission electron microscopy 
(TEM) imaging on a 200 kV FEI Tecnai Osiris microscope (Hillsboro, OR, USA). X-rays emitted 
from the specimens were collected via four symmetrically arranged energy dispersive X-ray 
spectrometers. Signals from all four detectors were combined into one x-ray energy dispersive 
spectroscopy (EDS) spectrum to improve collection efficiency. EDS spectrums were created 
using Esprit imaging software (Bruker, Billerica, MA, USA). The specific energies of the EDS 
emission peaks were used to identify elements within each sample. 
Confirmation of Colistin-PEG3400-OPSS and NHS-PEG3400-OPSS conjugation to AuNPs 
Zeta potential measurements and size measurements were obtained with a Malvern 
Instruments Zetasizer (Malvern Nanosizer ZS, Malvern Instruments, U.K.) to determine surface 
charge and size of the Col-PEG-AuNPs, PEG-AuNPs, and unconjugated AuNPs. Each NP 
formulation was resuspended in dH2O (pH 7.5) at an AuNP concentration of 1.0 mM, respectively.  
H1 NMR spectroscopy was used to confirm colistin conjugation to the Col-PEG-AuNPs. 
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H1 NMR spectrums were recorded in deuterium oxide (D2O, Cambridge Isotope Laboratories, 
Inc., Andover, MA, Lot #: D2OR-14-06), pH 7.4 using a Bruker 600 MHz spectrometer (Bruker, 
600 MHz, Billerica, MA, USA). Col-PEG-AuNPs at a NP concentration of 5 mM were lyophilized 
for 24 h. The sample was resuspended in D2O and then centrifuged at 8,000g (21°C) for 30 min. 
The supernatant was decanted and analyzed using H1 NMR spectroscopy, prior to the iodination 
process described below.  
The sample pellet was resuspended in D2O and five iodine crystals were added. The 
iodinated Col-PEG-AuNP sample was vortexed for 10 s, every 20 min, for the total duration of 1 
h. Iodine is a nucleophile and, therefore, attacks the disulfide group present in the OPSS-
containing ligand54. During this reaction, nucleophilic substitution of iodine with the disulfide takes 
place, thereby causing quantitative decoupling of the OPSS-containing ligands from the surface 
of the AuNPs. Iodination of AuNPs reduces their aqueous solubility and forces them to 
spontaneously precipitate55, leaving only OPSS-containing ligand and iodine in the supernatant. 
Following 1 h of periodic vortexing, the sample was stored at 4°C for 24 h to allow the 
iodine crystals to settle at the bottom of the suspension. Then, only Colistin-PEG3400-OPSS ligand 
remained in suspension and was extracted for analysis using H1 NMR spectroscopy. The same 
procedure was used to analyze the NHS-PEG3400-OPSS ligand of the PEG-AuNPs. Also, free 
colistin sulfate (500 ng) in D2O was analyzed using H1 NMR spectroscopy. This low concentration 
of free colistin sulfate was chosen for H1 NMR analysis to prove that this method of analysis can 
detect the presence of colistin at minute concentrations.  
Functionalized nanoparticle storage stability 
The possibility of Colistin-PEG3400-OPSS ligand disassembly from the surface of the Col-
PEG-AuNPs was evaluated using H1 NMR spectroscopy. Col-PEG-AuNPs (5 mM) were 
resuspended in PBS, pH 7.4 and stored at 21°C. After 24h, the Col-PEG-AuNP sample was 
centrifuged at 8,000g (21°C) for 30 minutes. Following centrifugation, the supernatant was 
decanted and analyzed using H1 NMR spectroscopy to detect possible release of Colistin-
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PEG3400-OPSS ligands from the surface of the functionalized nanoparticles. This analysis was 
also performed 24h, 48h, 72h, and 7 days following Col-PEG-AuNP storage (21°C) in PBS, pH 
7.4. 
Cell culture 
HepG2 cells (human liver carcinoma cancer cell line) were cultured in Dulbecco's modified 
Eagle's medium (DMEM, Gibco Cell Culture, Carlsbad, CA, USA) supplemented with 10% fetal 
bovine serum (FBS, Gibco) at 37°C in a humidified atmosphere containing 5% CO2. HUVEC cells 
(human umbilical vein endothelial cell line) were cultured in vascular basal cell medium (American 
Type Culture Collection (ATCC) PCS-100-300, Manassas, VA, USA) supplemented with 
endothelial cell growth kit-VEGF (ATCC PCS-100-41) at 37°C in a humidified atmosphere 
containing 5% CO2. 
In vitro cytotoxicity studies 
The cytotoxicity induced by Col-PEG-AuNPs, PEG-AuNPs, and free colistin sulfate on 
mammalian cell cultures was determined using the alamarBlue (Invitrogen Co., Carlsbad, CA, 
USA) assay56. HepG2 and HUVEC cells were seeded in clear, flat 96-well plates at a density of 
10,000 cells/well in 200 μL of medium and incubated for 24 h at 37°C. Next, culture medium was 
removed and exchanged with medium containing fresh Col-PEG-AuNPs and PEG-AuNPs at 
concentrations of 2, 1, 0.5, 0.25, and 0 mM, respectively.  Cells were also treated with free colistin 
sulfate at concentrations of 900, 90, 70, 15, 1 and 0 μM. After incubation for 24 h at 37°C, cells 
were washed three times with phosphate buffer solution (PBS), pH 7.4 and treated with 200 μL 
of alamarBlue containing media. Cells were then incubated for an additional 4 h at 37°C. 
Fluorescence was quantified using a plate-reader (Tecan, Infinite M1000 Pro, Switzerland), with 
an excitation wavelength of 540 nm and emission wavelength of 590 nm.  
In vitro hemocompatibility 
Human whole blood was collected from anonymous, consenting human donors in 
accordance with an approved Institutional Review Board (IRB) protocol (IRB 111251). Red blood 
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cells (RBCs) were isolated according to well-established protocols57. Four different concentrations 
(2, 1, 0.5, 0.25, and 0 mM) of Col-PEG-AuNPs and PEG-AuNPs were prepared in PBS, pH 7.4, 
respectively. Free colistin sulfate (900, 0.9, 0.4, 0.2, and 0 μM) was also prepared in PBS, pH 7.4. 
Col-PEG-AuNPs, PEG-AuNPs, free colistin sulfate, positive control, and negative control were 
incubated with RBCs for 1h at 37°C, each respectively, at the concentrations outlined above. 
Following incubation, the samples were centrifuged (21°C) and the supernatant was 
spectrophotometrically analyzed for hemoglobin release using a plate-reader (Tecan, Infinite 
M1000 Pro) at 451 nm in order to determine percent hemolysis relative to the Triton-X positive 
control. Triton X-100 (Sigma-Aldrich) was diluted in diH2O to result in a 20 v/v % Triton-X detergent 
concentration, which served as the positive control. The negative control used was PBS, pH 7.4. 
Percent of hemoglobin release was calculated according to the following equation:  
Hemoglobin	release	% = (𝑆𝑎𝑚𝑝𝑙𝑒789	:; 		− Negative	control789	:;)(Positive	control789	:; 	− 	Negative	control789	:;) ∗ 100%							(2.1) 
A. baumannii strains and culture conditions 
A. baumannii type strains ATCC 17978 and ATCC 19606 were obtained from the 
American Type Culture Collection (ATCC). Colistin-resistant variants of ATCC 19606 (designated 
19606C) were isolated according to well-established procedures58. Briefly, A. baumannii strain 
ATCC 19606 was directly plated onto LB-agar (Lennox L Agar, Research Products International 
Corp., Lot # 32687) containing 4 μg/ml of colistin sulfate. Colistin-resistant colonies were identified 
at a frequency of approximately 1 in 108 after a single round of selection. All A. baumannii strains 
were maintained on LB-agar or cultured LB broth (Lennox L Broth, Research Products 
International Corp., Lot # 30728) at 37°C, with the addition of 4 μg/ml of colistin sulfate where 
appropriate. 
A. baumannii binding 
A. baumannii (ATCC 17978) was grown in LB broth at 37ºC, 200 rpm until reaching late 
log phase. The A. baumannii culture (5x108 CFU/ml, pH 7.4) was exposed to Col-PEG-AuNPs (1 
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mM NPs) for 1 hour at 37ºC, 200 rpm prior to centrifugation at 8,000g (21°C) for 20 min to pellet 
the cells. The supernatant was discarded, and the cells were washed two times with sterile DI 
water prior to imaging. To fix the cells, 2% formaldehyde was added, and the samples were 
incubated for 30 min at 21°C. Droplets of Col-PEG-AuNP bacteria suspension were deposited on 
carbon film-backed copper grids (Ted Pella Inc., 400 mesh Cu, Lot # 250315) and blotted dry. A 
200 kV FEI Tecnai Osiris microscope was used for high angle annular dark field-scanning 
transmission electron microscopy (HAADF-STEM) imaging and simultaneous EDS spectrum 
analysis. Imaging was performed using the STEM mode capabilities of the microscope, thereby 
providing suitable conditions for high angle annular dark field imaging (HAADF). Data collection 
was carried out using the HAADF detector of the FEI Tecnai Osiris microscope, which collects 
scattered electrons emitted from the sample with an annular dark-field detector. By using HAADF-
STEM, it was possible to form atomic resolution images, in which contrast is directly related to 
atomic number. This allowed for determination of the location and distribution of the Col-PEG-
AuNPs with respect to the A. baumannii.  The same procedure was repeated using PEG-AuNPs. 
Image analysis was carried using Bruker Esprit software. 
AuNP standard concentration curve 
The concentration of AuNPs was quantified using absorbance techniques, from which a 
standard concentration curve was generated. AuNPs were resuspended in PBS, pH 7.4 and 
diluted to various concentrations (2.0, 1.5, 1.0, 0.75, 0.5, 0.25, 0.12, 0 mM). 200 μL of each 
sample was plated in a 96-well plate. Absorbance was quantified using a plate-reader (Tecan, 
Infinite F500, Switzerland), with an absorbance wavelength of 492 nm. A standard concentration 
curve was generated from the data and is represented by the following equation: 𝑦 = 0.9193𝑥 + 0.014;	𝑅P = 0.9976																																																	(2.2) 
where x represents AuNP concentration (mM) and y represents absorbance at 492 nm. 
A. baumannii binding kinetics 
The rate of nanoparticle association to A. baumannii (ATCC 17978, ATCC 19606, ATCC 
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19606C) was analyzed using a spin filtration/absorbance technique. Initially, A. baumannii was 
grown in LB at 37ºC, 200 rpm until reaching late log phase. A. baumannii diluted in PBS, pH 7.4 
(5x108 CFU/ml) was then exposed to Col-PEG-AuNPs (1 mM) and PEG-AuNPs (1 mM), 
respectively, for various times (0, 5, 10, 20, 30, 60, 120 min) prior to centrifugation at 4,900g 
(21°C) for 1 min to pellet the nanoparticle-bound bacteria. 200 μL of the supernatant was plated 
in a 96-well plate. Absorbance was quantified using a plate-reader (Tecan Infinite F500), with an 
absorbance wavelength of 492 nm. Results were then compared to the AuNP standard 
concentration curve in order to determine the concentration of nanoparticles unbound to bacteria. 
From this, the number of nanoparticles bound to bacteria was estimated. This procedure was 
completed for all three A. baumannii strains (ATCC 17978, ATCC 19606, ATCC 19606C). 
Statistical analysis 
All experiments were performed in triplicate. The results were expressed as the arithmetic 
mean ± standard deviation (SD). One-way analysis of variance (ANOVA) was used to determine 
whether there were any significant differences between the means of independent groups. 
Tukey's post hoc test was utilized to discriminate between groups of means. The factor was 
declared significant if the probability of the null hypothesis was less than 5% (p-value < 0.05). 
Ethical compliance  
Human whole blood was collected from anonymous donors in accordance with an 
approved IRB protocol (IRB 111251). 
 
Results and Discussion 
Preparation of Col-PEG-AuNPs and PEG-AuNPs 
Colistin was tethered to AuNP surfaces using heterobifunctional PEG, as depicted in 
Figure 2.1. NHS was used to couple the PEG group to one of the five similarly reactive L-α-
diaminobutyric acid (Dab) residues of colistin through the amine side chain of Dab59. Upon 
entering an aqueous environment, the NHS group of the NHS-PEG3400-OPSS linker covalently 
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binds to any single, comparably reactive amine residue of the colistin antibiotic via carbodiimide 
chemistry, resulting in an amide bond60,61. The disulfide group of the OPSS end of the 
heterobifunctional PEG has a strong affinity for the gold surface of the AuNPs62. Therefore, use 
of the PEG heterobifunctional linker enabled colistin decoration of the AuNP with a PEG molecular 
spacer, which was designed to reduce steric hindrance of colistin binding to bacteria. Thiolated 
PEG (HS-PEG2000) was used to passivate the AuNP surface unoccupied by the Colistin-PEG3400-
OPSS. This additional PEG was intended to further passivate the Col-PEG-AuNPs, reduce 
nonspecific binding onto the gold surface, and sterically stabilize the NPs in both biological and 
non-biological fluids. In the range of physiological pH values, between pH 7.0 and 8.5, the primary 
amine groups of colistin were protonated, and, therefore, positively charged63,64. The positive 
charge of colistin allowed for binding to the negatively charged outer membrane of A. baumannii42. 
PEG-AuNPs were synthesized using a very similar, multistep approach, and used as a control 
group that lacked colistin decoration. 
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Figure 2.1. Synthesis scheme of Col-PEG-AuNP. 
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Characterization of functionalized AuNPs 
TEM images consisted of highly mono-disperse NPs, as shown in Figure 2.2a-c, with an 
average NP core size of 23.2 nm. The EDS capabilities of the TEM confirmed the presence of 
gold in the NP core by characteristic X-rays at 2.120, 9.712, and 11.442 KeV (Fig 2.2d).  
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Figure 2.2. TEM, representative images of nanoparticles. (a) AuNP, (b) PEG-AuNP, (c) Col-PEG-
AuNP. d, TEM-EDS of Col-PEG-AuNPs verified the presence of Au in the sample, confirming the 
nanoparticle core composition. The copper (Cu) signals were a result of the carbon film-backed 
copper grids used.  
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Confirmation of Colistin-PEG3400-OPSS and NHS-PEG3400-OPSS conjugation to AuNPs 
The successful conjugation of Colistin-PEG3400-OPSS and NHS-PEG3400-OPSS to AuNPs 
was confirmed through zeta potential, size, and H1 NMR spectroscopy measurements. The zeta 
potential of Col-PEG-AuNPs was significantly greater than control PEG-AuNPs or untreated 
AuNPs (Table 2.1). This increase in zeta potential was consistent with decoration of the AuNPs 
with strongly cationic colistin. 
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Table 2.1. Functionalization of AuNPs with NHS-PEG3400-OPSS or Colistin-PEG3400-OPSS 
significantly increased AuNP zeta potential (z) towards more positive values. ANOVA and Tukey’s 
post hoc test prove that both Col-PEG-AuNP and PEG-AuNP zeta-potentials are significantly 
different than AuNP zeta-potential. Also, Col-PEG-AuNP and PEG-AuNP zeta-potentials are 
significantly different comparatively.  *p < 0.05  
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Passivating the AuNPs through PEGylation alone reduced the zeta potential of untreated 
AuNPs, presumably due to the partial shielding of the original surface charge. The addition of 
colistin to the Col-PEG-AuNPs further increased the zeta potential, presumably due to the colistin 
molecule corona, which is cationically charged at physiological pH values.  
Size measurements of the PEG-AuNPs and Col-PEG-AuNPs (Fig 2.3a) supported ligand 
conjugation to the AuNPs and allowed an estimation of ligand length. The Colistin-PEG3400-OPSS 
ligand was approximately 8.5 nm in length when bound to AuNPs, based on a diameter that was 
roughly 17 nm larger than that of unconjugated AuNPs. Conjugation of NHS-PEG3400-OPSS had 
a similar effect on size, thereby providing further confidence of the successful generation of PEG-
AuNPs.  
The hydrodynamic radii of Col-PEG-AuNPs were smaller than those of PEG-AuNPs, as 
reported by DLS (Fig 2.3b). Attraction of the positively charged colistin molecules to the negatively 
charged AuNP surface was presumed to change the PEG linker conformation, resulting in the 
observed decrease in ligand length, relative to PEG-AuNPs that have a much greater negative 
zeta potential. 
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Figure 2.3. Functionalization of AuNPs with NHS-PEG3400-OPSS or Colistin-PEG3400-OPSS 
significantly increased AuNP size. a, Nanoparticle diameter (d) was estimated by DLS. b, Mean 
size of each nanoparticle. ANOVA and Tukey’s post hoc test prove that both Col-PEG-AuNP and 
PEG-AuNP size are significantly different than AuNP size. Also, Col-PEG-AuNP and PEG-AuNP 
size are significantly different comparatively.  *p < 0.05  
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H1 NMR spectroscopy confirmed conjugation of colistin to the AuNPs (Fig 2.4a). The 
Colistin-PEG3400-OPSS ligands were treated with iodine to decouple the ligands from the AuNP 
surface and then measured using H1 NMR65. This decoupling approach was utilized in order to 
prevent peak broadening due to the presence of AuNPs in the sample. 
H1 NMR results are shown in Figure 2.4, with the supernatant from iodine treated Col-
PEG-AuNPs shown in Figure 2.4a and free colistin sulfate shown in Figure 2.4b. The protonated 
amine groups of colistin are identifiable in both spectrums (Fig 2.4a, 8.31ppm; Fig 2.4b, 8.38 
ppm), consistent with successful conjugation of colistin to the AuNPs. Conjugation of colistin to 
the PEG3400-OPSS linker was expected to cause diamagnetic shielding, increasing the electron 
density surrounding the colistin molecule. The physical shift of the protonated colistin amine peak 
upfield, as seen by comparing Figure 2.4a to Figure 2.4b, is consistent with diamagnetic shielding 
and is further evidence that the colistin was bound to the PEG3400-OPSS linker. 
The supernatant of Col-PEG-AuNPs without the addition of iodine was also analyzed 
using H1 NMR (Fig 2.4c) over the course of 7 days. This analysis was performed in order to 
estimate the amount of colistin containing molecules that were not particle bound and possibly 
released from the surface of the nanoparticles over time. The relative gain and number of counts 
taken to generate the H1 NMR spectrums of the non-iodinated Col-PEG-AuNP samples were 
scaled to allow direct comparison to the iodinated Col-PEG-AuNP H1 NMR spectrum.  
Due to the absence of a protonated amine peak (8.31 ppm) in the H1 NMR spectrum of 
non-iodinated Col-PEG-AuNPs (Fig 2.4c), it was concluded that the amount of colistin ligand 
released from the surface of the nanoparticles was below the NMR mass limit of detection (500 
ng), and, therefore, insignificant. Stoichiometry of the reaction and H1 NMR data support a 
concentration of colistin bound to particles of 3.9 μM colistin/mg AuNP, or 3400 colistin ligands 
per AuNP. This reflects approximately 95% of total AuNP surface coverage, based on a 0.35 nm2 
PEG footprint area66. This was the maximum number of colistin containing ligands that could be 
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loaded onto the surface of a single AuNP while remaining water dispersible. The H1 NMR 
spectrum of iodine treated PEG-AuNPs is shown in Figure 2.4d. It can be seen that no signal was 
present at 8.31 ppm, indicating the absence of colistin in the sample.   
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Figure 2.4. H1 NMR spectrums of Col-PEG-AuNP supernatant verified that the colistin-containing 
molecules were bound to AuNPs. a, Supernatant of iodinated Col-PEG-AuNPs. The peak 
indicated at 8.31 ppm was assigned to the protonated amine groups of colistin. The presence of 
protonated amine groups in (a) confirmed successful colistin conjugation. b, Free colistin sulfate 
(mass of 500 ng). The peak indicated at 8.38 ppm was assigned to the protonated amine groups 
of colistin. c, Supernatant of pelleted, non-iodinated Col-PEG-AuNPs stored in PBS, pH 7.4 
(21ºC). Following 0h, 24h, 48h, 72h, and 7 days, no peak was present at 8.31 ppm, indicating a 
colistin concentration lower than the limit of detection. This demonstrates that no significant 
amount of colistin ligand was released from the surface of the nanoparticles during storage. d, 
Supernatant of iodinated PEG-AuNPs. No peak was present at 8.31 ppm, indicating the absence 
of colistin. 
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In vitro cytotoxicity studies 
AlamarBlue is a cell membrane-permeable dye that both changes fluorescent properties 
and color in response to a chemical reduction caused by cell metabolic activity67. With alamarBlue 
it is possible to compare control group cell viability against experimental group cell viability, from 
which cytotoxicity can be analyzed quantitatively. After a 24 h incubation period, the cell viability 
of mammalian cells treated with Col-PEG-AuNPs or PEG-AuNPs was no different than untreated 
cells (Ctrl) (Fig 2.5a, 2.5b).  
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Figure 2.5. (a) Col-PEG-AuNPs and (b) PEG-AuNPs demonstrated cellular compatibility with 
HUVEC and HepG2 cells. HUVEC and HepG2 cells were treated with different nanoparticle 
formulations at various concentrations. a, HUVEC and HepG2 cell viability was quantified by the 
alamarBlue viability assay following 24 h treatment with Col-PEG-AuNPs. b, HUVEC and HepG2 
cell viability was quantified by the alamarBlue viability assay following 24 h treatment with PEG-
AuNPs. Treatment with Col-PEG-AuNPs or PEG-AuNPs did not cause cell toxicity. Data were 
normalized to control cells (Ctrl, 0.0), and are shown as mean ± SD (n = 3). (p-values not 
significant). 
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Free colistin cytotoxicity was also evaluated in vitro using HepG2 and HUVEC mammalian 
cell lines with alamarBlue56. Cell viability above 90% was observed with free colistin sulfate 
concentrations equal to or less than 90 μM. In comparison, cell viability of only approximately 80% 
was observed when administering colistin sulfate at a concentration of 900 μM (Fig 2.6).  
The two forms of colistin commercially available are colistin sulfate and colistimethate 
sodium. It is recommended that colistin sulfate be used for colistin susceptibility testing59. 
However, colistimethate sodium is the less toxic of the two and, therefore, is used more frequently 
for parenteral use. After inactive colistimethate sodium is delivered parenterally, it is hydrolyzed 
in order to be converted to colistin and, therein, exhibit antibacterial activity59. The intravenous 
colistimethate sodium dosage recommended in the United States for sepsis treatment is about 
13 mg/kilogram (kg) of body weight per day59. The recommended doses for colistin base activity 
are 2.5–5 mg/kg per day in two to four divided doses. This is equivalent to about 6.67–13.3 mg/kg 
of colistimethate sodium per day59.  
Based on a 105 patient study by Nation et al., the steady-state plasma concentration of 
colistin ranges from 0.48 to 9.38 mg/liter (average 2.36 mg/liter) following a 200 mg median daily 
dose of colistin base activity68. This steady-state plasma concentration of 0.48 to 9.38 mg 
colistin/liter is equivalent to 0.42 μM to 8.1 μM colistin concentration. Therefore, the 90 μM colistin 
sulfate concentration evaluated in the mammalian cell culture model significantly exceeds the 
upper limit of steady-state plasma concentrations of colistin base activity. 
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Figure 2.6. Cellular toxicity was not induced by free colistin sulfate at concentrations less than 90 
μM. HUVEC and HepG2 cell viability was quantified by the alamarBlue viability assay following 
24 h treatment with colistin. Treatment with colistin sulfate caused cellular toxicity at a colistin 
sulfate concentration of 900 μM in both cell types. Data were normalized to control cells (Ctrl, 0), 
and are shown as mean ± SD (n = 3). *p < 0.05 compared to Ctrl.  
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In vitro hemocompatibility 
Avoiding destabilization and nonspecific interactions with cells and other blood 
components is key to general hemocompatibility and important for future applications of these 
materials in contact with blood. A design goal was to maximize the allowable duration for blood 
contact time with NPs in order to allow for passive bacterial association or active bacterial 
targeting by intact, bioactive NPs. Ex vivo experiments in human whole blood were done to 
measure nonspecific RBC interactions and the stability of AuNPs. After 1 h incubation in a solution 
of isolated RBCs, Col-PEG-AuNPs, PEG-AuNPs, and free colistin sulfate were retained in the 
serum fraction and did not cause hemolysis (Table 2.2, Table 2.3). PEGylation improves 
hemocompatibility of similarly sized NPs69, and we hypothesized that surface PEGylation could 
be an avenue to further enhance stability. The PEGylation design presumably contributed to the 
observed lack of adverse interactions between blood cells and Col-PEG-AuNPs. Greater 
opportunity for Col-PEG-AuNP interaction with A. baumannii is one consequence of the extended 
allowable blood contact time exhibited by these NPs.  
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Table 2.2. After 1 h incubation in a solution of isolated RBCs, Col-PEG-AuNPs and PEG-AuNPs 
were retained in the serum fraction and did not cause hemolysis. Four different concentrations of 
Col-PEG-AuNPs (2, 1, 0.5, 0.25, and 0 mM) and PEG-AuNPs (2, 1, 0.5, 0.25, and 0 mM) were 
prepared in PBS, pH 7.4, respectively. Samples were made in quadruplicate and hemolysis 
experiments were performed in quadruplicate. Triton-X (20 v/v %) was used as a positive control. 
The results were expressed as the arithmetic mean ± standard deviation (SD). 
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Table 2.3. After 1 h incubation in a solution of isolated RBCs, colistin sulfate was retained in the 
serum fraction and did not cause hemolysis. Four different concentrations of colistin sulfate (0.2, 
0.4, 0.9, and 900 μM) were prepared in PBS, pH 7.4, respectively. Samples were made in 
quadruplicate and hemolysis experiments were performed in quadruplicate. Triton-X (20 v/v %) 
was used as a positive control. The results were expressed as the arithmetic mean ± standard 
deviation (SD).  
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Nanoparticle binding to A. baumannii  
 The primary component of the outer membrane of Gram-negative bacteria, including A. 
baumannii, is LPS. LPS is composed of lipid A, a core oligosaccharide, and an outer 
polysaccharide. Lipid A is the innermost aspect of the LPS, as well as the most conserved 
component of the structure70. The proposed binding mechanism between colistin and A. 
baumannii involves lipid A. At physiological pH values, the primary amine groups of the colistin 
heptapeptide ring and fatty acid tail become protonated, thereby allowing electrostatic interactions 
with the negatively charged phosphate groups of lipid A42. Initial electrostatic interaction between 
colistin and A. baumannii leads to hydrophobic interaction between the fatty acid tail of colistin 
and the acyl chains of lipid A43. The conjugation chemistry of Colistin-PEG3400-OPSS was 
designed to preserve and protect the molecular characteristics of colistin that are responsible for 
antibiotic activity and binding to A. baumannii. Conjugation of colistin to the heterobifunctional 
PEG was hypothesized to use any single, similarly reactive amine group of the colistin 
heptapeptide ring. This colistin conformation leaves the four remaining, comparably reactive 
protonated amine groups of colistin in their active state and free to interact with the cell envelope 
of A. baumannii.  
Col-PEG-AuNPs associated with the cell envelope of A. baumannii (ATCC 17978), as 
imaged by STEM (Fig 2.7a). High-angle annular dark-field (HAADF)-STEM analysis of Col-PEG-
AuNPs association with A. baumannii (ATCC 17978), Figure 2.7b, verified that gold (Au) and 
nitrogen (N) were present in the sample, thereby confirming the presence of Col-PEG-AuNPs and 
bacteria71,72. In the HAADF-STEM image shown in Figure 2.7b, contrast is directly related to 
atomic number. This allowed for identification of chemical elements present in the sample. In this 
case, gold was pseudocolored to identify the Col-PEG-AuNPs (Fig 2.7c), whereas nitrogen was 
pseudocolored to identify the bacteria (Fig 2.7d). Further analysis of Figure 2.7b provided the 
complete elemental make-up of the sample (Fig 2.7, Fig 2.9). Figures 2.7a and 2.7b suggest that 
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Col-PEG-AuNPs attached to the surface of A. baumannii.  PEG-AuNPs did not bind to the 
bacterial surface (Fig 2.7e), confirming that colistin is an effective targeting ligand. The HAADF-
STEM image shown in Figure 2.7f allowed for identification of chemical elements present in the 
PEG-AuNP sample. The EDS spectrum (Fig 2.10) verified the presence of bacteria through 
elemental analysis, but elemental gold was not present in the sample (Fig 2.7g, Fig 2.7h), 
indicating that PEG-AuNPs did not bind to A. baumannii. 
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Figure 2.7. HAADF-STEM imaging of Col-PEG-AuNP association with A. baumannii (ATCC 
17978) (a & b) suggests that the targeting ligand of colistin is required for nanoparticle binding to 
A. baumannii. a, STEM of Col-PEG-AuNPs bound to A. baumannii. b, HAADF-STEM view of the 
sample analyzed in panel (a). The sample was analyzed using HAADF techniques to form atomic 
resolution images in which gold (c) and nitrogen (d) are pseudo-colored. e, STEM of PEG-AuNPs 
incubated with A. baumannii. f, HAADF-STEM view of the sample analyzed in panel (e). The 
sample was evaluated for the presence of gold (g) and nitrogen (h) using HAADF techniques. 
The lack of gold in (g) indicates that PEG-AuNPs were not associating with A. baumannii.  
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Figure 2.8. EDS spectrum of Figure 2.7b confirmed that Col-PEG-AuNPs, indicated by Au peaks, 
were associated with A. baumannii, indicated by phosphate (P), potassium (K), sodium (Na), 
nitrogen (N), and chlorine (Cl) peaks. The Cu signals were a result of the carbon film-backed 
copper grids used.  
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Figure 2.9. HAADF-STEM images in combination with EDS further confirmed the elemental 
composition of A. baumannii. N, K, Cl, P, and Na are the core elements that make up A. 
baumannii.    
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Figure 2.10. EDS spectrum of PEG-AuNPs incubated with A. baumannii lacks Au, indicating that 
PEG-AuNPs were not bound to A. baumannii. P, K, Na, and Cl peaks confirmed the presence of 
bacteria. The Cu signals were a result of the carbon film-backed copper grids used.   
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A. baumannii binding kinetics 
Col-PEG-AuNP binding to A. baumannii was characterized as a function of the extent of 
colistin decoration per NP (Col:NP ratio), holding the NP:A. baumannii ratio constant. Fastest 
binding occurred when using a 3.9 μM colistin concentration functionalized to the AuNP surface, 
which is consistent with colistin base plasma concentrations seen in the clinical setting68. To 
achieve a 3.9 μM colistin concentration, approximately 3400 Colistin-PEG3400-OPSS ligands were 
bound to a single AuNP, based on the molecular dimensions of PEG and number of AuNPs. The 
kinetics of Col-PEG-AuNP association with A. baumannii was characterized by a spin filtration 
technique as described in the Methods section. Following the addition of A. baumannii to Col-
PEG-AuNPs, the rate of association was evaluated over a 2 h time period. Col-PEG-AuNP 
association with A. baumannii was analyzed using three different strains of A. baumannii, which 
included ATCC 17978, ATCC 19606, and ATCC 19606C (colistin resistant). 
Nanoparticle attachment to A. baumannii was dependent upon the presence of the colistin 
targeting ligand, as shown in Figure 2.11. The rate of Col-PEG-AuNP binding to A. baumannii is 
described by a two-parameter, exponential curve in the form of: Α = ΑTUV ∗ 1 − 𝑒WX Y 																																																											(2.3) 
where Α (number) represents the number of Col-PEG-AuNPs bound to a single A. baumannii, 
and t (min) represents time. The constants for the exponential curve are ΑTUV (maximum number 
of Col-PEG-AuNPs per A. baumannii), the final asymptotic value of this system, and 𝜏 (min), the 
time constant.  
The maximum number of Col-PEG-AuNPs bound to a single A. baumannii (ΑTUV) varied 
from strain to strain. It was estimated that ΑTUV is approximately equal to 1228 Col-PEG-AuNPs 
per A. baumannii ATCC 19798 (Fig 2.11a). The time constant, 𝜏, represents the time required 
for 63% of maximal Col-PEG-AuNP binding per A. baumannii, or ΑTUV. In this system, 𝜏 is 
equivalent to 9.6 minutes. Therefore, in describing Col-PEG-AuNP binding to A. baumannii 
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strain ATCC 17978, Equation (2.3) can be more completely represented as: Α = 1228 ∗ 1 − 𝑒WX \.] 																																																													(2.4) 
Half-maximal binding in this case occurs when Α is equal to half of ΑTUV, or when 614 Col-PEG-
AuNPs are bound to a single A. baumannii ATCC 17978 cell (~6.7 min).  
It was estimated that ΑTUV  is approximately equal to 1182 Col-PEG-AuNPs per A. 
baumannii ATCC 19606 (Fig 2.11b). The time constant, 𝜏 , is equivalent to 10.2 minutes. 
Therefore, in describing Col-PEG-AuNP binding to A. baumannii strain ATCC 19606, Equation 
(2.3) can be represented as: Α = 1182 ∗ (1 − 𝑒WX 9^.P)																																																											(2.5) 
Half-maximal binding in this case occurs when 591 Col-PEG-AuNPs are bound to a single A. 
baumannii ATCC 19606 cell (~7.1 min). The association rate of Col-PEG-AuNPs with ATCC 
17978 is not significantly different than that of Col-PEG-AuNPs with ATCC 19606. This indicates 
that the Col-PEG-AuNPs associate similarly with both A. baumannii ATCC 17978 and A. 
baumannii ATCC 19606. 
The rate of Col-PEG-AuNP association with colistin resistant A. baumannii (ATCC 
19606C) was also evaluated. In this case, ΑTUV is approximately equal to 584 Col-PEG-AuNPs 
per A. baumannii ATCC 19606C (Fig 2.11c). The time constant, 𝜏, is equivalent to approximately 
10.7 minutes. Col-PEG-AuNP binding to A. baumannii strain ATCC 19606C can be represented 
as: Α = 584 ∗ (1 − 𝑒WX 9^.`)																																																												(2.6) 
Under these conditions, half-maximal binding occurs when 292 Col-PEG-AuNPs are bound to a 
single A. baumannii ATCC 19606C cell (~7.4 min). The ΑTUV value associated with Col-PEG-
AuNP binding to colistin resistant A. baumannii (ATCC 19606C) is significantly less than the ΑTUV 
values seen in Equations (2.4) and (2.5). It is proposed that this is most likely due to changes in 
the outer membrane of colistin resistant A. baumannii (ATCC 19606C), which would affect the 
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binding of colistin to the bacterial cell59.   
The kinetic analysis suggests that the binding rate, 𝜏 , of colistin-functionalized 
nanoparticles to colistin resistant A. baumannii (ATCC 19606C) is equal to that of colistin sensitive 
strains (ATCC 19606 and ATCC 17978). However, the maximum number of colistin binding 
events per A. baumannii cell is significantly reduced by colistin resistance, as measured by ΑTUV. 
These results are consistent with functional LPS at a reduced surface concentration on colistin 
resistant A. baumannii.   
The PEG-AuNP control samples, in the absence of colistin, did not exhibit time dependent 
binding behavior with any of the three strains of A. baumannii that were evaluated (Fig 2.11a, 
2.11b, and 2.11c). This further confirmed that nanoparticle attachment to A. baumannii was 
dependent upon the presence of the colistin targeting ligand. Colistin is effective as a targeting 
ligand even in the case of colistin resistant A. baumannii (ATCC 19606C), as seen in Figure 2.11c. 
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Figure 2.11. Col-PEG-AuNPs rapidly and specifically associated with A. baumannii (ATCC 
17978, ATCC 19606, ATCC 19606C), whereas PEG-AuNPs did not specifically bind the bacteria. 
a, Col-PEG-AuNPs rapidly and specifically associated with A. baumannii (ATCC 17978), reaching 
50% maximum saturation within 6.7 min, whereas PEG-AuNPs did not specifically bind the 
bacteria. b, Col-PEG-AuNPs rapidly and specifically associated with A. baumannii (ATCC 19606), 
reaching 50% maximum saturation within 7.1 min, whereas PEG-AuNPs did not specifically bind 
the bacteria. c, Col-PEG-AuNPs specifically associated with colistin-resistant A. baumannii 
(ATCC 19606C), reaching 50% maximum saturation within 7.4 min, whereas PEG-AuNPs did not 
specifically bind the bacteria. For all three A. baumannii strains evaluated, including colistin 
resistant (ATCC 19606C), interaction of Col-PEG-AuNPs with A. baumannii was significantly 
different than the interaction of PEG-AuNPs with A. baumannii. ANOVA and post hoc analysis 
prove that Col-PEG-AuNP binding to A. baumannii is significantly different than that of PEG-
AuNPs at all time points.    
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Conclusions 
This work, for the first time, presented a mathematical description of the binding kinetics 
between colistin-functionalized nanoparticles and three different A. baumannii strains, including 
a colistin resistant strain. The novel nanoparticle system with colistin as an A. baumannii targeter 
covalently conjugated to the distal end of PEG eliminated the possibility of colistin disassembly 
through electrostatic interactions. Additionally, the use of a ligand presumably reduced colistin 
steric hindrance and increased nanoparticle-bacteria association.  
Colistin-functionalized nanoparticles specifically associated with A. baumannii, whereas 
PEG-AuNPs did not. The rapid rate of nanoparticle-bacteria association mediated through colistin 
enables the consideration of new approaches to bacterial detection and isolation. Colistin is 
projected to support extraction of particle-bound A. baumannii using methods similar to Singh et 
al. and Lee et al.24,52. Because colistin is FDA approved and readily available, this design may be 
further developed and translated for use in the clinical setting and for water purification purposes. 
Rapid, colistin mediated binding of nanoparticles to A. baumannii also potentially enables new 
advances in the detection and purification of Gram-negative bacteria from other environmental 
samples, such as food and soil. 
 
Summary 
A colistin functionalized nanoparticle that combines the properties necessary to target and 
bind to Acinetobacter baumannii, including drug-resistant variants, was designed, fabricated, and 
characterized. A comparable variant of the colistin functionalized nanoparticle, a PEGylated 
nanoparticle, was fabricated and characterized to substantiate the results and conclusions of this 
study. The colistin functionalized nanoparticle was carefully designed and tuned to promote rapid 
bacterial binding while reducing colistin steric hindrance through the use of a heterobifunctional 
linker. Utilizing colistin as a targeting motif is advantageous because it is a readily available and 
has been used in the clinical setting for decades. This design simplifies development and 
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facilitates regulatory considerations relative to the use of genetically engineered or new 
biomacromolecular ligands. Results support the claims that: (1) colistin functionalized 
nanoparticles were fabricated and (2) colistin can be used as targeting motif to capture A. 
baumannii, including (3) drug-resistant variants. This work successfully fulfills Specific Aim 1 
of this dissertation. Furthermore, this work was published in the Journal of Biomedical 
Nanotechnology, Volume 12, Issue 9 (Fig 2.12) 73. 
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Figure 2.12. Publication in Journal of Biomedical Nanotechnology, Volume 12, Issue 9 73. 
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Gold nanoparticles (AuNPs) were functionalized for rapid binding of Acinetobacter baumannii (A. baumannii), a Gram-
negative bacterium. AuNPs were functionalized with colistin (Col), a polycationic antibiotic, using a two-step self-assembly
process, in which heterobifunctional polyethylene glycol (PEG) was used as a linker. Colistin was successfully conjugated
to the AuNPs (Col-PEG-AuNP), as validated by dynamic light scattering (DLS) and proton nuclear magnetic resonance
(H1 NMR). High angle annular dark field scanning transmission electron microscopy (HAADF-STEM) images, acquired
simultaneously with X-ray energy dispersive spectroscopy (EDS) data, confirmed binding of Col-PEG-AuNPs to the cell
envelope of A. baumannii. Results generated from a binding assay indicated that Col-PEG-AuNP complexation with
A. baumannii occurred rapidly and reached half-maximum saturation in approximately 7 minutes, on average, for all
A. baumannii strains evaluated. Quantitative measurement of the kinetics of Col-PEG-AuNP binding to A. baumannii is
essential to inform the design of colistin-functionalized magnetic nanoparticles for magnetic separation of nanoparticle-
bound A. baumannii.
KEYWORDS: Gold Nanoparticles, Colistin, Acinetobacter baumannii, Multi-Drug Resistance, Gram-Negative, Lipopolysaccharide.
INTRODUCTION
Acinetobacter baumannii, a Gram-negative coccobacillus
with a multi-drug resistant (MDR) phenotype, is com-
monly found in soil, water, mucous membranes, vegeta-
bles, and on human skin.1 Individuals with a compromised
immune system, diabetes, or wounds can suffer from life-
threatening infections resultant from A. baumannii. Infec-
tions caused by A. baumannii can lead to widespread
inflammation, blood clotting, multiple organ failure, pneu-
monia, septic shock, and death.1 A. baumannii is respon-
sible for 2% to 10% of Gram-negative bacterial infections
worldwide and has an associated mortality rate reaching
up to 60%.2–4
The spread of A. baumannii occurs via human con-
tact and through contact with contaminated food, soil,
water, and hospital equipment.5 A. baumannii has been
detected in freshwater ecosystems, sewage, wastewater,
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drinking water, and groundwater supplies.5!6 Infections
resultant from A. baumannii and other Gram-negative bac-
teria can be transmitted by contaminated drinking water.7
Various adsorption columns have been developed for the
removal of bacteria from fluid.8–10 Unfortunately, these
devices have drawbacks due to slow, diffusion-limited
operation and surface sites, which decrease the adsorption
capacity of the adsorbent. Separation of adsorbents from
bulk medium can be complex. Thus, the development of
adsorbents with higher adsorptive capacity, low diffusion
resistance, and fast separation is of great importance in
practical engineering applications.
Recently, alternative approaches have been sought to
address the shortcomings of current treatments for var-
ious bacterial contaminations and infections. In particu-
lar, bacteria-targeting magnetic nanoparticles (MNPs) have
been developed for the separation of MNP-bound bac-
teria from wastewater or blood using external magnetic
fields.11!12 Nanoparticles have a high surface area to vol-
ume ratio, which enables high adsorption efficiency. Singh
et al. have reported that surface-engineered MNPs allow
1806 J. Biomed. Nanotechnol. 2016, Vol. 12, No. 9 1550-7033/2016/12/1806/014 doi:10.1166/jbn.2016.2273
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CHAPTER III 
 
DYNAMIC COMPUTATIONAL MODEL TO INFORM BACTERIAL SEPARATION 
REQUIREMENTS  
The rise of multi-drug resistance has decreased the effectiveness of antibiotics, which has 
led to increased mortality rates associated with symptomatic bacteremia, or bacterial sepsis. To 
combat decreasing antibiotic effectiveness, extracorporeal bacterial separation approaches have 
been proposed to capture and separate bacteria from blood. However, sepsis is dynamic and 
involves host-pathogen interactions across various anatomical sites. I developed a mathematical 
model that quantitatively describes the kinetics of pathogenesis and progression of sepsis under 
various conditions, including bacterial separation therapy, to better understand disease 
mechanisms and quantitatively assess the biological impact of bacterial separation therapy. 
Model validity was tested against experimental data from published studies. This is the first multi-
compartment model of sepsis in mammals that includes extracorporeal bacterial separation and 
antibiotic treatment, separately and in combination. 
The addition of an extracorporeal bacterial separation circuit reduced the predicted time 
of total bacteria clearance from the blood of an immunocompromised rodent by 49%, compared 
to antibiotic treatment alone. Implementation of bacterial separation therapy resulted in predicted 
multi-drug resistant bacterial clearance from the blood of a human in 97% less time than antibiotic 
treatment alone. The model also proposes a quantitative correlation between time-dependent 
bacterial load among tissues and bacteremia severity, analogous to the well-known ‘area under 
the curve’ for characterization of drug efficacy. The engineering-based mathematical model 
developed may be useful for informing the design of extracorporeal bacterial separation devices. 
This work enables the quantitative identification of the characteristics required of an 
extracorporeal bacteria separation device to provide biological benefit. These devices will 
potentially decrease the bacterial load in blood. Additionally, the devices may achieve bacterial 
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separation rates that allow consequent acceleration of bacterial clearance in other tissues, 
inhibiting the progression of sepsis, including multi-drug resistant variations. Results from this 
chapter will fulfill Specific Aim 2 of my dissertation.  
 
Introduction 
Symptomatic bacteremia is a common cause of severe sepsis74. In the United States, 
Gram-negative bacteria cause approximately 70% of hospital acquired infections in intensive care 
units75, while up to half of all bloodstream infections are caused by Gram-negative bacilli76. 
Infections caused by Gram-negative bacteria are of particular concern because these organisms 
are highly efficient at acquiring and up-regulating various mechanisms that promote multi-drug 
resistance (MDR)77. Global concern revolves around the ever-increasing number of infections 
caused by MDR Gram-negative bacteria, in particular Acinetobacter baumannii and Klebsiella 
pneumoniae59.  
A. baumannii and K. pneumoniae are both Gram-negative bacilli with MDR phenotypes. 
These bacteria are commonly found in the hospital setting and reside in internal parts of the 
human body44,78. One of the strongest risk factors for developing a Gram-negative bloodstream 
infection is a compromised immune system. More specifically, those suffering from neutropenia, 
or lack of neutrophils in the blood, run a significantly higher risk for developing a bloodstream 
infection than healthy individuals79,80. A. baumannii and K. pneumoniae infections can lead to 
multiple consequences, such as widespread inflammation, blood clotting, multiple organ failure, 
pneumonia, septic shock, and death. The crude mortality rate associated with an A. baumannii or 
K. pneumoniae bloodstream infection in an immunocompromised patient can exceed 70%79,81,82.  
Treatment of a bloodstream infection requires eradication of bacteria from the blood, but 
also from other tissues, including the source of infection. The clearance of bacteria by the host 
immune response is similar to the pharmacokinetic clearance of drugs. Therefore, the clearance 
of bacteria from the host may be interpreted using a multi-compartment model with each 
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compartment representing a tissue into which bacteria may enter and exit, replicate, or be 
eliminated by treatment. Bacteria can be transferred among tissues and eventually be eliminated 
through an immune response, therapeutic treatment, or a combination of both. Unlike drugs, 
bacteria proliferate prior to host recognition, and bacteria continue to proliferate in the case of an 
unsuccessful host defense.  
Bacterial clearance from the bloodstream in a physiologically based pharmacokinetic 
(PBPK) model was first described in 1983 by Cheewatrakoolpong et al.83. The group analyzed 
the kinetics of bacterial clearance from the blood and mesenteric lymph nodes of mice using a 
two-compartment computational model. More recently, Kang et al. developed a mathematical 
model that predicts bacterial clearance solely from the bloodstream26. In the Kang et al. model, 
the group incorporated the effects of an extracorporeal bacterial separation device that 
continuously removes bacteria from flowing blood using a magnetic nanoparticle-based 
separation technique. The mathematical model successfully predicted the optimal magnetic 
nanoparticle sizes required for removal of bacteria from whole blood. This model enabled 
predictions of particle–pathogen collision and magnetophoresis rates, which allowed for 
determination of how these factors influence magnetic pathogen separation from blood under flow 
using a microfluidic magnetic separation device. The biological impact of bacterial separation in 
the host, however, was not incorporated into this model.  
 The work by Kang et al. can be expanded into a five-compartment model that accounts 
for physical and immunological interactions, bacterial net growth, transport among tissues (lungs, 
spleen, liver, blood), antibiotic treatment, and extracorporeal removal of bacteria from the blood. 
This type of expanded, dynamic model can be used to characterize time-dependent, tissue-
specific bacterial load in symptomatic bacteremia. Also, such a model could be used to 
characterize the biological impact of bacterial separation from the blood, and, potentially, predict 
the utility as a therapeutic treatment option in conjunction with antibiotic treatment. Consequently, 
we developed a pharmacokinetic model of A. baumannii and K. pneumoniae sepsis in order to 
 56 
provide a quantitative and flexible framework useful for both experimental and analytical work in 
this area.  
A five-compartment dynamic model, consisting of five first-order homogenous ordinary 
differential equations, was developed to study the biodistribution of A. baumannii and K. 
pneumoniae during bacterial sepsis in mammals. This pharmacokinetic model was used to 
assess the combination of broad-spectrum colistin antibiotic treatment and extracorporeal 
bacteria separation from the blood on the overall time-dependent bacterial burden in infected 
living systems. Colistin, a naturally occurring cationic decapeptide isolated from Paenibacillus 
polymyxa var. colistinus53, is a potent broad-spectrum antimicrobial. This antibiotic is commonly 
used for the treatment of challenging Gram-negative pathogens84, including A. baumannii.  
The time course of a bacterial infection within important tissues of immunologically normal 
rodents was described using the mathematical model. The same measures were then used to 
examine the impact of suppressed immunity. The efficacy of antibiotic administration in 
immunosuppressed rodents exposed to a bacterial challenge was also analyzed. Finally, the 
potential benefit of extracorporeal bacterial isolation and removal from blood, in terms of bacterial 
load by compartment, was assessed in both rodent and human mathematical models.  
Analyzing results from this model of multi-organ infection with a PBPK mathematical approach 
provides an opportunity to evaluate the efficacy of extracorporeal bacterial separation from the 
bloodstream in combination with various antibiotic treatment regimens. For the first time, a 
modeling approach based on experimentally obtained data allows quantitative exploration of the 
impact of extracorporeal bacterial separation in combination with antibiotic treatment. 
 
Materials and Methods 
Kinetic Model and Parameter Values 
A five-compartment kinetic model was developed to explore the pathogenesis kinetics and 
treatment of sepsis (Fig 3.1). It was assumed that infection occurred via intratracheal instillation 
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of a 107 CFU/mL Gram-negative bacteria (Acinetobacter baumannii or Klebsiella pneumoniae) 
bolus into the lung compartment. This is a common bacterial concentration used to establish and 
study rodent sepsis models85. Also, the most common site of infection leading to sepsis in humans 
is the lungs86,87. Bacterial exchange among all five compartments, which included the lungs, 
spleen, liver, blood, and bacterial separation device, was programmed as specified by the model 
construction and parameters extracted from experimental studies of sepsis. The lungs, liver, 
spleen, and blood were included because all have experimentally demonstrated the most 
significant and rapid uptake of blood-borne bacteria88. Kinetics were assumed to be first order. 
Bacteria proliferated (p (h-1)) within the lungs, spleen, liver, and blood, and were cleared (c) by 
immunological interactions at rates (h-1) specific to each compartment. No experimental evidence 
was available to distinguish p from c in vivo, therefore, the two terms were considered as a single 
net bacterial growth rate (Gx (h-1)). Bacterial transport between compartments was represented 
as a function of the blood flow rate, Q, the compartment volume, V, and a partitioning coefficient, 
x88. The partition coefficient represented the ratio of bacteria concentration between 
compartments and was proportional to the concentration of bacteria in the donor compartment88. 
Bacterial separation efficiency, f(rf), represented the percent of target bacterial cells separated by 
the bacterial separation compartment (CFU mL-1) per total number of target bacterial cells (CFU 
mL-1). 
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Figure 3.1. The five-compartment kinetic model describing bacterial pathogenesis. Intratracheal 
instillation of a Gram-negative bacteria bolus initially occurred in the lung compartment, with initial 
concentration L0 (CFU mL-1). Bacterial proliferation rates (p, h−1), clearance rates (c, h−1), and 
transport rates between compartments were included in the model schematic. The rate of 
bacterial transport between compartments was represented as a function of blood flow rate per 
compartment volume (Q/V, mL h-1), modified by an experimentally determined partitioning 
coefficient (x, dimensionless).  
  
 59 
Five first-order homogenous ordinary differential equations (ODEs) were used as a model 
representation of the physiological features of the system. The system of equations was based 
on previously published pharmacokinetic models88,89. Each autonomous ODE represented the 
instantaneous rate of change of bacteria concentration in the respective compartment, 𝑑𝐿𝑑𝑡 = 𝐺e ∗ 𝐿 + 𝑄e𝑉e ∗ 𝐵 −	 𝑄e𝑉e𝑥e ∗ 𝐿 																																													(3.1) 𝑑𝑆𝑑𝑡 = 𝐺i ∗ 𝑆 + 𝑄i𝑉i ∗ 𝐵 −	 𝑄i𝑉i𝑥i ∗ 𝑆 																																													(3.2) 𝑑𝐻𝑑𝑡 = 𝐺k ∗ 𝐻 + 𝑄k𝑉k ∗ 𝐵 + 𝑄i𝑉i𝑥i ∗ 𝑆 − 𝑄k + 𝑄i𝑉k𝑥k ∗ 𝐻 																											(3.3) 𝑑𝐸𝑑𝑡 = 𝑄m𝑉m ∗ 𝐵 ∗ 𝑓 𝑟p − 	 𝑄m𝑉m𝑥m ∗ 𝐸 ∗ 1 − 𝑓 𝑟p 																																(3.4) 𝑑𝐵𝑑𝑡 = 𝐺q ∗ 𝐵 + 𝑄k + 𝑄i𝑉k𝑥k ∗ 𝐻 + 𝑄e𝑉e𝑥e ∗ 𝐿 + 	 𝑄m𝑉m𝑥m ∗ 𝐸 ∗ 1 − 𝑓 𝑟p
− 𝑄k𝑉k +	𝑄i𝑉i + 	𝑄e𝑉e + 𝑄m𝑉m ∗ 𝑓 𝑟p 	 ∗ 𝐵 																																																																									(3.5) 
where L, S, H, E, and B were the bacterial concentrations (CFU mL-1), in the lungs, spleen, liver, 
extracorporeal bacterial separation device, and blood, respectively.  The model was designed 
such that bacteria were transported from the spleen into the liver via hepatic portal circulation. 
Liver (H, hepatic) circulation was divided into splenic portal venous blood and the combination of 
hepatic arterial flow and its tributaries. Mouse and human organ mass values were based on 
published literature and were used to describe organ volumes, V88. Organ blood flow rates, Q, 
and blood:organ partition coefficients, x, were also gathered from previously published data88. 
Empirical values used to describe compartmental volumes, blood flow rates, and partition 
coefficients can be found in Table 3.1a and 3.1b and Table 3.2. 
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Table 3.1a. Model parameters, rodent88. 
 
Table 3.1b. Model parameters, human90–93. 
 
Table 3.2. Partition coefficient model parameters88. 
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The rodent model was based on 58.5 ml of blood per kg of bodyweight94. A mouse 
weighing 31 g would have a total blood volume of approximately 1.80 mL. Subsequent 
calculations were scaled to account for the 5000 mL average total blood volume of humans.  
The net bacterial growth rates, Gx, in each compartment of non-immunocompromised 
subjects, along with immunocompromised neutropenic subjects, can be found in Table 3.3a and 
3.3b. These values were derived from published literature in which the total bacterial burden was 
measured in each compartment of a rodent over a specific period of time. This data has not been 
reported for human subjects. Therefore, net bacterial growth rates in human compartments were 
based on rodent models.  
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Table 3.3a. Net bacterial growth rates, A. baumannii88,95–98. 
 
Table 3.3b. Net bacterial growth rates, K. pneumonia99–101. 
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Net bacterial growth rates corresponding to each compartment following colistin antibiotic 
treatment are displayed in Table 3.4a and 3.4b102,103. Experimental evidence was not available to 
distinguish p from c in vivo. However, it was possible to deduce single net bacterial growth rates 
(Gx (h-1)) by analyzing literature that reported the total bacterial burden in each compartment 
before and after colistin treatment.  
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Table 3.4a. Net bacterial growth rates, A. baumannii with colistin103. 
 
Table 3.4b. Net bacterial growth rates, K. pneumoniae with colistin102,103. 
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Magnetic Separation Component Design 
The bacterial separation (E) component of the model embodied a fluidic device in which 
continuous magnetic separation of Gram-negative bacteria from non-Newtonian particulate blood 
flow occurred. The magnetic separation device consisted of two steps, together comprising the 
total magnetic separation efficiency, f(rf): 1) Gram-negative bacteria–targeted magnetic 
nanoparticles bound to the bacterial cells and 2) the magnetic separation of nanoparticle-bacteria 
complexes from the blood. Total magnetic separation efficiency, f(rf), of bacteria from the blood 
was dependent upon magnetic nanoparticle size, blood viscosity, and magnetic forces. The 
modeling parameters and equations used to calculate the value of f(rf) were based on previous 
studies26,104.  
Briefly, the value of f(rf) was calculated for various nanoparticle sizes by determining the 
binding kinetics between the magnetic nanoparticles and bacteria. Assuming that all bacteria 
bound to magnetic nanoparticles were removed by the magnetic fluidic device, the binding 
efficiency, x(rf), was represented by 𝑥 𝑟p = 1 −	𝑒 Wrs tuvtwxsyz ∗{∗X ∗ 100																																													(3.6) 
where b was the concentration of magnetic nanoparticles, kd the diffusion collision rate constant, 
kshear the shear collision rate constant, and ce (3.7 * 10-4 <dimensionless>) an empirical constant 
representing the binding efficiency of bacteria to the magnetic nanoparticles in whole blood26.  
Then, the effects of the magnetophoretic separation of the magnetic nanoparticle-bound 
bacteria from the blood under continuous flow were determined. The magnetic forces acting on 
the magnetic nanoparticle-bound bacteria directly impacted the magnetic separation efficiency. 
Therefore, the magnetic separation efficiency was estimated by calculating the magnetic force 
induced by our defined theoretical parameters,  
𝐹;U} = 𝑁 ∗ 	4𝜋𝑟p3 ∗ Δ𝜒2𝜇 ∗ 𝐵P																																																						(3.7) 
where rf was the radius of a magnetic nanoparticle, μo was the magnetic permeability of vacuum 
 66 
(4π * 10-7 < T m A-1> ), B2 was the magnetic field intensity (B2 = 40 < T2 m-1>), N was the number 
of magnetic nanoparticles bound to the bacteria cell, and Δχ (<dimensionless>) was the 
volumetric susceptibility of the magnetic nanoparticles104. The following conditions were used: 
Δ𝜒 = 	4 ∗ 3.5 ∗ 	𝜋 ∗ 	𝑟p3 																																																														(3.8) 
𝑁 = 4 ∗ 	𝜌 ∗ 	 𝑟r𝑟p P 																																																																	(3.9) 
where rc was the effective spherical radius of a pathogen (0.5 μm, A. baumannii
73; 0.65 μm, K. 
pneumoniae105) and it was assumed, based on previous literature, that half of the cell surface was 
covered by magnetic particles (ρ = 0.5 <dimensionless>)26,104. 
Assuming a quasi-static motion,  𝐹;U} = 𝐹U} = 6𝜋𝑟:𝜂𝑣;U}																																																						(3.10) 
where rn was the effective hydraulic radius of the bacteria–nanoparticle complex and η was the 
blood viscosity (4 * 10-3 <N s m-2>)26. The variable rn can be represented as 
𝑟: = 	 𝑟r + 𝑁 ∗ 𝑟p 																																																																			(3.11) 
For small particles, Fmag = Fdrag and, therefore, the magnetophoretic velocity (vmag) of the magnetic 
nanoparticle-bacteria complex can be defined as 
𝑣;U} = 	 𝑟:P𝑁Δ𝜒𝐵P9𝜂𝜇 																																																																			(3.12) 
Blood flowing through the magnetic extraction fluidic component at a flow rate of Q (L h-1) resulted 
in an average linear velocity (v1) of bacteria labeled with magnetic nanoparticles of  
𝑣9 = 	𝑄𝑎 																																																																														(3.13) 
where a was the cross-sectional area of the device channel (0.002 m x 0.0006 m; width x height)26. 
The characteristic residence time, tres, of the nanoparticle-bound bacteria in the magnetic fluidic 
device channel was approximated by 
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𝑡i = 	 𝐿e𝑣9 																																																																														(3.14) 
where LL was the hypothetical length of the channel (LL = 0.027 m)26. The magnetophoretic 
transverse time (tmag), the time it takes the nanoparticle-bound bacteria to be extracted from the 
blood by the magnets of the fluidic device, was described by 
𝑡;U} = 	 𝐿𝑣;U} 																																																																								(3.15) 
where Lh was the height of the magnetic fluidic device channel (0.0006 m)
26.  
The magnetic separation efficiency, m(rf), was then estimated by comparing the 
characteristic residence time (tres) to the time required for the nanoparticle-bound bacteria to be 
extracted from the blood by the magnets of the fluidic device (tmag)26.  𝑚(𝑟p) = 100 ∗ 	 𝑡i𝑡;U} 	 , 𝑡i < 	 𝑡;U}																																															(3.16) 𝑚(𝑟p) = 100	, 𝑡i ≥ 	 𝑡;U}																																																				(3.17) 
Finally, the total magnetic separation efficiency, f(rf), for the two-step process was calculated 
using 𝑓 𝑟p = 	 𝑥(𝑟p) ∗ 𝑚(𝑟p)																																																								(3.18) 
Maximum magnetic separation of bacteria from blood was predicted to occur when using 
magnetic nanoparticles with 25 nm radii. As the magnetic nanoparticle radius increased, the 
extraction efficiency decreased (Fig 3.2). Experimental and theoretical results from Kang et al. 
were used to validate this trend26. 
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Figure 3.2. Magnetic separation efficiency, f(rf), of Gram-negative bacteria incubated with 
bacteria-targeting magnetic nanoparticles in whole blood. In the model predictions, the maximum 
magnetic separation efficiency occurred using magnetic nanoparticles with a radius of 25nm. The 
theoretical model prediction was verified by comparison to results published by Kang et al.26. 
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Model Analysis 
All analysis was written in Matlab R2015b (The Mathworks, Inc, Natick, Mass). The model 
equations were solved using the appropriate ODE solver in Matlab. The parameters values were 
verified by fitting the solution of the differential equations to experimental data found in literature. 
 
Results and Discussion 
Time Course of Bacterial Infection in Immunonormal Rodents  
Non-immunocompromised rodents challenged intratracheally with a prepared inoculum of 
either A. baumannii 107 CFU/mL or K. pneumoniae 107 CFU/mL85,106 were modeled. The overall 
bacterial burden for both Gram-negative species decreased over time in all compartments, 
although at different rates (Fig 3.3a and 3.3b). The blood compartment of the non-
immunocompromised rodent mathematical model required the least amount of time to clear 
bacteria to a negligible amount (≤ 1 CFU/mL), followed by the spleen, lungs, and liver. The 
bacterial clearance trends shown in Figure 3.3a and 3.3b were compared to experimental studies, 
in which total bacterial burden was reported for the liver, spleen, lungs, and blood of non-
immunocompromised rodents following intratracheal bacterial challenge88,95,96,107–109. Within 24 
hours of intratracheal bacterial challenge, the total bacterial uptake by the liver was the largest, 
and was followed by the spleen, lungs, and blood107. The results of our model were in agreement 
with experimental results previously described88,95,96,107–109. Bruhn et al. experimentally 
demonstrated that an A. baumannii bacterial load of 104 CFU/mL within the blood compartment 
of a normal rodent model was reduced to negligible bacterial densities at a rate of -0.06 log10 
CFU/mL/h97. This A. baumannii clearance rate, characteristic of the non-immunocompromised 
rodent blood compartment, was in agreement with in our model predictions (Fig 3.3a). The blood 
compartment bacterial load dropped to half maximal concentration within approximately 40 hours 
of the onset bacterial challenge. This rate of bacterial clearance within the blood compartment 
was equivalent to -0.06 log10 CFU/mL/h.  Also, Guo et al. have reported that normal rodents 
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infected intratracheally with an A. baumannii bolus clear the infection from the lungs at a rate of 
–0.1 log10 CFU/mL/h95. The average A. baumannii clearance rate within the lung compartment of 
the dynamic model was also -0.1 log10 CFU/mL/h (Fig 3.3a), corresponding to published 
experimental data. Furthermore, the A. baumannii bacterial burden within the liver of a normal 
rodent decreased at a rate of -0.06 log10 CFU/mL/h96, which was the same liver clearance rate 
produced by the mathematical modeling results.  
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Figure 3.3. Bacterial burden decreased over time in tissue compartments of healthy rodents. 
Immunonormal rodents intratracheally inoculated with (a) A. baumannii (107 CFU/mL) or (b) K. 
pneumoniae (107 CFU/mL) were modeled. The median numbers of bacteria in each compartment 
observed experimentally were used as the initial conditions for these simulations96–100, and 
trajectories were generated using the parameter estimates described in the Materials and 
Methods. 
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The mathematical model predictions were in quantitative agreement with experimental 
studies conducted by other laboratories. The model includes numerous physiological and 
microbiological parameters, which were chosen from first principles, not mathematical 
estimations. The agreement of model predictions with experimental data supports the validity of 
the model structure as representative of bacterial sepsis. The kinetic profiles of A. baumannii and 
K. pneumoniae concentration by tissue were similar for each set of assumptions evaluated in this 
work. Therefore, the remaining analysis of pathogenesis kinetics is described only for A. 
baumannii. The similar K. pneumoniae data is available in Appendix A.  
Figure 3.3 suggests that an immunonormal rodent suppresses bacterial growth, with 
bacterial clearance from each compartment following a pattern of exponential decay. Model initial 
conditions were 3 hours post-inoculation, focusing the modeling effort on the slower processes of 
bacterial removal rather than the rapid distribution of bacteria110. Bacteria rapidly spread from the 
lungs to the bloodstream, which resulted in bacterial transport to other organs. The hematogenous 
spread of bacteria to other organ sites initially caused a rapid decrease in the bacterial burden of 
the blood compartment, but spread of infection increased the time required to suppress the 
infection.   
Time Course of Bacterial Infection in Immunocompromised Rodents 
A. baumannii and K. pneumoniae Gram-negative bacteria frequently cause sepsis in 
immunocompromised, neutropenic, elderly, and chronically ill individuals111. To better evaluate 
such cases, we modeled the onset of sepsis in neutropenic, immunocompromised rodents. 
Without treatment, the overall bacterial burden increased in neutropenic rodents until reaching a 
bacterial load associated with death112,113. This experimental condition was modeled in Figure 3.4. 
The fitted model agreed with published experimental data regarding bacterial burden over time in 
an untreated, immunocompromised rodent model95. Previously published experimental data 
demonstrated that a pulmonary A. baumannii bacterial burden within an immunocompromised 
rodent increased at a rate of +0.04 log10 CFU/mL/h95,110, which was consistent with the 
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mathematical modeling results (Fig 3.4). Modeling results also suggest that the A. baumannii 
bacterial burden associated with the blood compartment increased at a rate of +0.05 log10 
CFU/mL/h, which was consistent with the experimental data published by Bruhn et al97.  
Approximately 100 hours following intratracheal exposure to 107 CFU/mL A. baumannii, 
neutropenic rodents succumb to the bacterial challenge103,114. This was consistent with the lethal 
bacterial concentration of 1010 CFU/mL at 96 hours predicted by mathematical modeling103,113–115. 
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Figure 3.4. Bacterial burden increased over time in neutropenic rodents until reaching a lethal A. 
baumannii concentration. The median numbers of bacteria in each compartment observed 
experimentally in previous literature were used as the initial conditions for these simulations98,101, 
and trajectories were generated using the parameter estimates shown in Materials and Methods. 
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The bacterial burden increases within the lungs, blood, and spleen compartments of 
Figure 3.4 are consistent with changes in bacterial transport out of the bloodstream, not simply 
suppressed bacteria clearance. Predictions obtained for the untreated, immunocompromised 
rodent model generated bacterial concentrations known to be lethal. Blood flow through the 
bacterial separation device compartment was set to zero in this scenario. All modeling parameters 
acquired and implemented were gathered directly from published experimental results and can 
be found in the Materials and Methods. Solutions from this multi-compartmental model were 
obtained in the absence of fitting parameters and mimicked experimental data, supporting the 
validity of the model.  
Efficacy of Antibiotic Administration in Infected, Immunosuppressed Rodents  
The most common treatment for sepsis is empiric, broad-spectrum antibiotic therapy. 
Therefore, colistin methanesulfonate antibiotic administration was incorporated into our 
mathematical model following the presentation of sepsis-like symptoms, which was presumed to 
occur when the bacterial concentration in the lungs reached 107 CFU/mL110 and bacteria were 
completely distributed throughout all compartments. Bacteria rapidly distribute throughout the 
blood, liver, lungs, and spleen following exposure88.  
Following simultaneous intratracheal infusion of 107 CFU/mL A. baumannii and 3 mg/kg 
colistin methanosulfate, A. baumannii was cleared from the blood of the neutropenic rodent 
mathematical model within 55 hours (Fig 3.5). The rate constants pertaining to bacterial clearance 
following colistin methanosulfate administration were based on experimental data gathered 
experimentally by Pantopoulou et al. and Montero et al103,116, as described in the Materials and 
Methods. The mathematical modeling (Fig 3.5) agreed with experimental data regarding the 
effects of colistin methanosulfate administration (3 mg/kg) on an A. baumannii bacterial burden in 
neutropenic rodent models, clearing the bacterial infection from the blood at a rate of -0.09 log10 
CFU/mL/h103,116.  
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Figure 3.5. A. baumannii burden decreased post inoculation in immunocompromised rodents 
treated with colistin methanosulfate (3 mg/kg). The associated parameters are shown in Materials 
and Methods.  
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The area under the curve (AUC) was computed for each compartment displayed in Figure 
3.5. The AUC reflects the total, time-dependent bacterial load experienced by each compartment 
of our model. Of note, the rodent mathematical model suggests that the liver consistently 
experienced the highest total bacterial burden, approximately an order of magnitude greater than 
the lungs, as indicated in Table 3.5. This result is consistent with the severe side effects observed 
during antibiotic treatment for sepsis, especially in immunocompromised and chemotherapy 
patients.  
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Table 3.5. A. baumannii burden experienced by immunocompromised rodent model administered 
colistin antibiotic. 
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Extracorporeal Bacterial Separation from Blood  
Kang et al. have described the development of an extracorporeal bacterial separation 
device that can remove bacteria from blood25. The Kang et al. device employs magnetic 
nanoparticles to magnetically remove pathogens, including multi-drug resistant bacteria, from 
flowing blood in a microfluidic device. Experimental results using this magnetic nanoparticle-
based bacterial separation device suggested that it significantly reduced the levels of bacteria in 
the blood of a rodent model. It was hypothesized that the spread of bacteria to distal organs would 
be significantly lowered with the decrease in bacterial concentration in the bloodstream25. Also, it 
was postulated that broad-spectrum antibiotic therapy, such as colistin methanosulfate, could be 
co-administered with this bacterial separation therapy, resulting in faster bacterial clearance rates.  
Magnetic nanoparticle-based extracorporeal bacterial separation could prove to be an 
effective adjuvant therapy for sepsis treatment. To test this hypothesis, an extracorporeal bacterial 
separation device was incorporated into the kinetic mathematical model, integrating predictions 
of magnetic bacteria separation under microfluidic flow in combination with colistin 
methanosulfate antibiotic treatment. The approach was used to explore the possible benefits of 
magnetic nanoparticle-based bacterial separation from blood in conjunction with antibiotic 
treatment on the time-dependent bacterial load among organs during sepsis.  
Bacterial Separation Combined with Antibiotic Therapy  
The predicted effect of extracorporeal bacterial separation for the purpose of clearing A. 
baumannii from the blood is demonstrated in Figure 3.6. Addition of magnetic nanoparticle-based 
bacterial separation operating at an ideal 100% efficiency and processing one-fifth of the total 
blood volume per hour, in conjunction with antibiotic treatment, resulted in A. baumannii clearance 
from the blood compartment in 27 hours less time than antibiotic treatment alone (Fig 3.6). 
Bacterial clearance rate associated with this combined treatment was 49% faster than antibiotic 
treatment alone (Table 3.6). This is a significant result because for each hour that a septic patient 
is not effectively treated, the risk of mortality increases by 7.6%117.  
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Figure 3.6. Bacterial separation (100% efficiency) combined with antibiotic administration 
improved A. baumannii clearance rate. A. baumannii cleared from the blood compartment of the 
immunocompromised rodent model in 28 h when implementing bacterial separation (100% 
efficiency) and antibiotic treatment. Antibiotic administration alone resulted in bacterial clearance 
from the blood compartment in 55 h. 
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Table 3.6.  A. baumannii clearance (≤1 CFU/mL) time improved upon addition of 100% efficient 
bacterial separation. 
 
Table 3.7. Bacteria separation in immunocompromised A. baumannii rodent model reduced 
bacterial burden experienced. 
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The AUCs of Figure 3.6 were also evaluated. The model suggested that the liver 
experienced a 52% reduction in AUC with the addition of bacterial separation in the presence of 
antibiotic (Table 3.7). With bacterial separation occurring at 100% efficiency, the extracorporeal 
bacterial separation device had a significant impact on overall bacterial clearance and diffusion 
rates. The total bacterial burden in the blood compartment decreased by an order of magnitude 
compared to antibiotic treatment alone. Also, the incorporation of the 100% effective bacterial 
separation device into the model inhibited bacterial proliferation and diffusion from the initial 
inoculation point of the lungs, thereby lowering the overall bacteria burden in all compartments.  
Device Optimization Based on Bacterial Separation Efficiency 
Bacterial separation efficiency has a significant impact on the rate of bacteria removal 
from the blood compartment (Fig 3.7). As previously displayed in Table 3.6, 100% separation 
efficiency promoted the clearance of A. baumannii from the blood in 27 hours less time than 
antibiotic treatment alone. To explore the role of separation efficiency on predicted bacterial load 
in vivo, model analysis was carried out for separation efficiencies of 60% and 20%. This approach 
was intended to inform the design constraints of extracorporeal bacteria separation devices for 
impact in complex living systems. 60% bacterial separation efficiency resulted in clearance of A. 
baumannii from the blood compartment in 20 hours less time that antibiotic treatment alone (Table 
3.8). As the separation efficiency further decreased to 20%, bacterial removal became ineffective. 
Therefore, device design features that impact bacterial separation efficiency and nonlinearly 
influence clearance must be considered for proposed applications. 
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Figure 3.7. Bacterial separation (100% and 60% efficiency) improved A. baumannii clearance 
rates from the blood compartment. 20% bacterial separation efficiency was not efficient enough 
to impact the overall bacterial clearance rate and resulted in the same clearance rates as antibiotic 
treatment alone.  
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Table 3.8. A. baumannii clearance (≤1 CFU/mL) time in immunocompromised rodent model 
accelerated with improved bacterial separation efficiencies. 
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Total bacteria separation efficiencies produced by the mathematically modeled 
extracorporeal separation devices were dependent on nanoparticle size. As the nanoparticle 
radius increased, the bacterial separation efficiency decreased, resulting in slower clearance of 
bacteria from blood (Fig 3.8). The collision rate constant decreased as the nanoparticle radius 
increased, resulting in less total nanoparticle interaction with, and binding to, bacteria26. Once the 
nanoparticle radius exceeded approximately 40 nm, the efficiency of bacterial binding and capture 
was not significant enough to impact the overall rate of bacterial clearance. The optimal 
nanoparticle size for bacteria capture and removal was estimated to be 25 nm or less, which 
directly corresponded to previously published literature26. The reduced mass of smaller 
nanoparticles, however, decreases the magnetic attraction force26. Thus, careful attention to the 
design of the separation device is required to achieve efficiency compatible with predicted 
improvement in overall bacterial clearance. Therefore, multiple, interconnected nanotechnology 
design features are important considerations in magnetic nanoparticle-based bacterial separation 
devices. 
The impact of bacterial separation efficiency was evaluated by the mathematical model 
and reported in terms of resultant total bacterial load, or AUC, experienced by each tissue 
compartment of an A. baumannii infected immunocompromised rodent. As the nanoparticle radius 
increased above 25 nm, the overall separation efficiency characteristic of the extracorporeal 
bacterial separation device decreased. Table 3.9 demonstrated that as the nanoparticle radius 
increased above 25 nm, the total bacterial burden experienced by each compartment also 
increased. All other parameters held constant, a nanoparticle radius of 43 nm is equivalent to a 
20% separation efficiency, which has no significant effect on the AUC compared to antibiotic 
treatment alone. Therefore, in order for magnetic nanoparticle-based bacterial separation devices 
to aid in the reduction of the total bacterial burden within each compartment, the efficiency of 
bacterial separation from the blood compartment must exceed 20%.   
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Table 3.9. Bacteria separation efficiencies greater than 20% reduced bacterial burden in A. 
baumannii immunocompromised rodent model. 
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Bacterial Separation for Treatment of Bacterial Sepsis in Human Model 
The use of extracorporeal bacterial separation for treatment of sepsis in humans has never 
been explored experimentally or by mathematical modeling. The successful rodent model was 
modified to explore the possible benefits of magnetic nanoparticle-based extracorporeal bacterial 
separation in humans during an episode of sepsis. By incorporating human parameters into the 
model and adjusting for the tissue volume differences of humans compared to rodents, we were 
able to estimate the impact of bacterial separation, in conjunction with antibiotic treatment. The 
model extrapolation to humans has known, and, likely, unknown limitations. However, this 
approach is a first step towards an understanding of the extracorporeal bacterial clearance 
necessary for biological impact.  
Sepsis occurs in an adult humans when the bacterial burden reaches approximately 10 
CFU/mL in the bloodstream or 103 CFU/mL in the lungs118–120. Therefore, our model incorporated 
these parameters as markers to indicate the time at which to apply extracorporeal bacterial 
separation and antibiotic treatment. Results suggested that A. baumannii clearance from the 
blood compartment was reduced by 14 hours with the addition of 100% efficient extracorporeal 
bacterial separation treatment, compared to antibiotic treatment alone (Fig 3.8). The flow rate 
through the bacterial separation compartment was programmed to process one-fifth of the total 
human blood volume per hour, similar to the blood flow rates used during kidney dialysis in 
humans. Based on the AUCs of Figure 3.8, the combination therapy approach decreased the total 
bacterial burden in the model compartments, with the most significant difference in the blood 
compartment (Table 3.10).  
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Figure 3.8. Bacterial separation (100% efficiency) with antibiotic treatment improved A. 
baumannii clearance from human blood compartment.  This combination treatment resulted in A. 
baumannii clearance (≤1 CFU/mL) from the blood compartment in 1 h. The time required for A. 
baumannii to be cleared to a negligible concentration (≤ 1 CFU/mL) from the blood compartment 
of the human model with antibiotic administration alone was 15 h.  
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Table 3.10. Bacteria separation (100% efficiency) in A. baumannii human model reduced 
bacterial burden experienced. 
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This work is the first to estimate, by mathematically models, bacterial load as a surrogate 
of the ultimate biological impact of infection. Bacterial load, or AUC, is directly correlated to the 
progression of sepsis and death121. Therefore, extracorporeal bacterial separation devices 
designed to operate at high efficiencies would not only significantly reduce the total bacterial load, 
but may also inhibit the progression of sepsis. Inhibition of disease progression would provide 
additional time to identify ideal therapies for infected patients, while reducing the mortality rates 
associated with sepsis.  
Bacterial Separation for Treatment of Multi-Drug Resistant Sepsis in Human Model 
Bacterial species identification in the clinical setting takes one to three days, a time during 
which the patient is treated with broad-spectrum antibiotics. This method is not optimal, especially 
for patients suffering from MDR infections. Sepsis caused by a MDR infection is one of the most 
critical public health issues, even in first-world countries122. The increasing frequency of MDR 
bacterial strains is leading into the ‘post-antibiotic era’.  
MDR-associated sepsis was mathematically modeled by assuming that the MDR A. 
baumannii were 50% less susceptible to antibiotic treatment than non-MDR A. baumannii. 
Bacterial infection that is 0% susceptible to antibiotic treatment behaves similarly to the trajectory 
shown in Figure 3.4 of untreated infection, whereas infection that is 100% susceptible to antibiotic 
treatment was shown in Figure 3.5. Choosing a MDR A. baumannii susceptibility of 50% allows 
for quantitative evaluation of model sensitivity to the degree of bacterial antibiotic resistance. 
Figure 3.9 described the clearance of MDR A. baumannii using the additional assistance of 100% 
efficient extracorporeal bacterial separation, compared to antibiotic treatment alone. The addition 
of extracorporeal bacterial separation operating at 100% efficiency resulted in MDR A. baumannii 
clearance from the blood of a human mathematical model in 1 h, which was 97% faster than 
antibiotic treatment alone. Antibiotics prove less effective in the treatment of MDR sepsis, which 
highlights the need for alternative treatment methods. Bacterial separation treatment methods 
have been shown to bind and remove multiple clinical isolates of antibiotic-resistant organisms25. 
 91 
This supports the development of new engineering-based bacterial separation devices to combat 
MDR bacteria and delay progression to septic shock. 
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Figure 3.9. Treatment of MDR A. baumannii human model using 100% efficient bacterial 
separation with antibiotic treatment. Using this combination therapy, MDR A. baumannii clearance 
(≤ 1 CFU/mL) from the blood compartment of the human mathematical model occurred in 1 h. 
The time required for MDR A. baumannii to be cleared to a negligible concentration (≤1 CFU/mL) 
from the blood compartment with antibiotic administration alone was 29 h.   
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Conclusions 
Mathematical modeling established that extracorporeal bacterial separation reduced the 
total bacterial burden in the bloodstream of a septic subject by an order of magnitude, compared 
to antibiotic treatment alone. This correlated to a 49% reduction in non-MDR bacterial exposure 
time due to the addition of extracorporeal bacterial separation therapy. Efficient bacterial 
separation also reduced the spread of bacteria to distal sites. Results further indicated that 
engineering-based bacterial separation devices could offer a particularly effective therapeutic 
strategy for patients suffering from MDR infections that render existing drug therapies inadequate. 
The addition of extracorporeal bacterial separation resulted in MDR bacterial clearance from the 
blood of a human mathematical model in 97% less time than antibiotic treatment alone. This was 
a notably important prediction because decreasing the length of bacterial infection significantly 
reduces the risk of mortality associated with sepsis117. The lack of antibiotics in the developmental 
pipeline, combined with the increasing rate of MDR, has created a dire need for the discovery of 
new therapies effective against MDR bacterial infections. Therefore, development of 
mathematical models is necessary to rapidly determine the effectiveness of new treatment 
therapies, such as extracorporeal bacterial separation. Our work was the first dynamic 
mathematical model to demonstrate the potential usefulness of extracorporeal bacterial 
separation for the treatment of sepsis and its MDR counterpart.  
Engineers have had a profound impact on the development of disease treatment systems, 
such as kidney dialysis devices. It is clear that engineers also have a role to play in the design of 
extracorporeal bacterial separation devices. To aid in the optimization of bacterial separation 
device design, more experimental data quantifying bacterial load in living systems must be 
gathered to better understand the correlation between bacterial load and patient outcome.  
Currently, data describing bacterial load in rodent systems is sparse, and corresponding 
human data is even less prevalent. These are key pieces of information that must be obtained in 
order to confidently design new treatment methods that reduce total bacterial burden, duration of 
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infection, and the ‘post-antibiotic era’ threat. Designing extracorporeal bacterial separation 
devices that remove bacteria from the blood at a rate deemed biologically relevant by this 
information may inhibit the progression of sepsis, decrease overall mortality rates, and help 
combat MDR bacterial infections. 
 
Summary 
Extracorporeal blood cleansing devices are of particular interest as they possess the 
potential capability of pathogen removal from whole blood in the absence of effective antibiotic 
treatment. This model of sepsis suggests that blood cleansing devices have the potential to 
significantly reduce the bacterial load in the blood of septic animals and humans. We have 
computationally modeled and predicted the effects of broad-spectrum antibiotic treatment with 
and without the addition of bacterial separation therapy in subjects suffering from sepsis. 
Implementing mechanical bacterial separation reduced duration of infection by 49% in model 
subjects suffering from antibiotic sensitive sepsis, according to our modeling predictions. 
Furthermore, our model predicted even more significant effects in subjects suffering from 
antibiotic resistant infection.  This work successfully fulfills Specific Aim 2 of this dissertation. 
Figure 3.10 highlights this work, which was featured in PLOS ONE, Volume 11, Issue 9 27.  
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Figure 3.10. Cover of work published in PLOS ONE, Volume 11, Issue 9 27. 
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Abstract
The rise of multi-drug resistance has decreased the effectiveness of antibiotics, which has
led to increased mortality rates associated with symptomatic bacteremia, or bacterial sep-
sis. To combat decreasing antibiotic effectiveness, extracorporeal bacterial separation
approaches have been proposed to capture and separate bacteria from blood. However,
bacteremia is dynamic and involves host-pathogen interactions across various anatomical
sites. We developed a mathematical model that quantitatively describes the kinetics of
pathogenesis and progression of symptomatic bacteremia under various conditions, includ-
ing bacterial separation therapy, to better understand disease mechanisms and quantita-
tively assess the biological impact of bacterial separation therapy. Model validity was
tested against experimental data from published studies. This is the first multi-compartment
model of symptomatic bacteremia in mammals that includes extracorporeal bacterial sepa-
ration and antibiotic treatment, separately and in combination. The addition of an extracor-
poreal bacterial separation circuit reduced the predicted time of total bacteria clearance
from the blood of an immunocompromised rodent by 49%, compared to antibiotic treatment
alone. Implementation of bacterial separation therapy resulted in predicted multi-drug resis-
tant bacterial clearance from the blood of a human in 97% less time than antibiotic treat-
ment alone. The model also proposes a quantitative correlation between time-dependent
bacterial load among tissues and bacteremia severity, analogous to the well-known ‘area
under the curve’ for characterization of drug efficacy. The engineering-based mathematical
model developed may be useful for informing the design of extracorporeal bacterial separa-
tion devices. This work enables the quantitative identification of the characteristics required
of an extracorporeal bacteria separation device to provide biological benefit. These devices
will potentially decrease the bacterial load in blood. Additionally, the devices may achieve
bacterial separation rates that allow consequent acceleration of bacterial clearance in other
tissues, inhibiting the progression of symptomatic bacteremia, including multi-drug resis-
tant variations.
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CHAPTER IV 
 
FLUIDIC PLATFORM FOR CAPTURE OF BLOOD-BORNE PATHOGENS 
The purpose of this chapter is to develop a microfluidic device capable of capturing A. 
baumannii from fluids. The double spiral microchannel is an attractive method for focusing micron-
sized particles, but has never been successfully implemented for bacteria. Using the double spiral 
fluidic platform, I was able to separate and focus various sized microparticles, as well as A. 
baumannii. I geometrically designed the double spiral fluidic platform to cause A. baumannii to 
streamline near the microchannel walls. Also, I functionalized the double spiral walls with colistin 
to promote A. baumannii capture within the device. Results from Chapter IV will fulfill Specific Aim 
3 of my dissertation. The work detailed in this chapter will be submitted for publication in a peer-
reviewed journal during February of 2017. 
 
Introduction 
The presence of bacteria in the circulatory blood initiates a cascade of local and systemic 
regulatory mechanisms that can result in sepsis1. Sepsis is the leading cause of death in the 
critically ill in the United States2,3. Currently, no specific sepsis treatment is available. Treatment 
relies on early recognition and rapid administration of appropriate antibiotics, fluid resuscitation, 
and vasoactive medications123,124. Early, effective antibiotic therapy is essential and improves 
patient outcomes125,126. However, sepsis-associated mortality remains unacceptably and 
persistantly high, highlighting the need for new sepsis therapies.  
Much research has been done to evaluate experimental adjunct treatments for sepsis, 
such as extracorporeal cytokine filtration127, recombinant human activated protein C128, 
corticosteroids129, human recombinant lactoferrin130, and immunomodulation131. Although 
immunomodulation has been widely anticipated, the heterogeneity of the patient population and 
the complexity of sepsis pathogenesis have limited advancement of these experimental 
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approaches. Blockage of single mediators, such as interleukin-1 (IL-1) or tumor necrosis factor-
alpha (TNF-a), has shown little promise in improving sepsis survival. Cytokine removal has 
displayed encouraging results in animal studies, however, results are believed to be a 
consequence of modulating other downstream mechanisms rather than the direct impact of 
cytokine removal132. Benefits of endotoxin clearance have shown efficacy in animal studies, but 
have yet to demonstrate improvement of septic patient outcomes29,133.  
Mechanical bacterial removal using magnetic nanoparticles has been reported to improve 
survival of septic rodent models25. Surface modification of nanoparticles using bacterial targeting 
ligands can lead to the efficient and reproducible capture of several important pathogenic 
bacteria52,73,134. However, these approaches suffer from potential limitations in scale-up for 
treatment of large living systems and uncertain regulatory hurdles in regard to blood contact with 
nanoparticles. Treatment addressing either a single molecular activator/inhibitor or isolation of the 
bacterial source is likely to insufficiently addresses the complexity of sepsis.  It is imperative to 
develop a clinically translatable, alternative therapy for sepsis that can remove both the 
pathogenic bacteria and modulate the resulting molecular effectors to help mitigate the systemic 
inflammatory response characteristic of sepsis and inhibit sepsis progression.  
We have designed and validated a blood purification device that is capable of removing 
endotoxin and Gram-negative bacteria, including drug resistant strains, from peripheral blood 
using inertial-based cell separation in combination with a broad-spectrum polycationic ligand. We 
expect that the device can be simply modified to also remove Gram-positive bacteria, providing a 
system capable of removing bacteria in the absence of strain identification, in addition to 
sequestering endotoxins. This device is based on a double spiral microfluidic design. We 
demonstrate, for the first time, the use of inertial-based forces for the focusing and separation of 
bacteria from flowing fluids, including whole, human blood.  This novel blood purification technique 
resulted in significant removal of bacteria and endotoxin from circulation, making this device a 
promising adjuvant treatment and potential diagnostic for sepsis and other pathogenic diseases. 
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Our technology is the first to overcome the issues observed in blood purification therapies that 
utilize membrane-based or column-type filters for removal of inflammatory mediators and other 
toxins from blood. Inertial-based focusing avoids clogging, poor efficiency of targeted element 
removal, and excessive removal of useful substances, such as blood components, which limit the 
translational potential of existing approaches.  
In laminar Poiseuille flow, the hyperbolic velocity profile has a maximum velocity at the 
centroid of the channel and zero velocity at the walls of the channel135. The lift forces (FL) acting 
on particles are dominated by wall-induced (F1) and shear-induced (F2) lift forces31,136,137. These 
lift forces act in conjunction to yield a particle equilibrium position between the channel wall and 
centerline where the oppositely directed lift forces are equal and generate narrow particle 
bands31,138–140. The net lift force (FL) that causes particles to migrate away from the channel center 
and walls is estimated as, FL = fL(Re,xL)rUm2ap4/Dh2, where the lift coefficient (fL) is a function of 
the channel Reynolds number Re (Re = rUmDh/µ) and the particle position (xL) within the cross-
section of the channel32,136,141. Dh is the microchannel hydraulic diameter, ρ and μ are the density 
and viscosity of fluid, Um is the maximum fluid velocity, and ap is the particle diameter. 
In curved microfluidic channels, non-uniform inertia of fluid results in the development of 
secondary transverse flows, or Dean vortex flows, in the top and bottom halves of the channel 
(Fig 4.1)31. The dimensionless Dean number (De), used to characterize the Dean vortex flow in a 
curved microchannel, can be defined as, De = (rUfDh)/μ)Ö(Dh/2R), where R is the radius of 
curvature and Uf is the average fluid velocity142. Assuming Stokes drag, the magnitude of the 
Dean drag force (FD) exerted on particles due to these flows can be estimated by142                            
FD = 5.4*10-4(p)(μ)(De1.63)(ap). 
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Figure 4.1. Asymmetry in a spiral channel. Transverse Dean flows exert a Dean drag force (FD) 
on particles flowing in a spiral channel. The competition between wall lift force, shear lift force, 
and Dean drag force results in differential migration of particles to unique equilibrium positions 
dependent of particle size143. 
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 The equilibrium positions of particles in flow are primarily determined by the interactions 
between lift forces and Dean drag force. The double spiral geometry in this design was formulated 
to cause bacteria-sized particles to occupy equilibrium positions near the microchannel walls 
when exposed to a flow rate of 0.2 mL min-1. This allows bacteria to come in close proximity to 
the polycationic ligand functionalized microchannel walls, which leads to bacteria and endotoxin 
capture. To accomplish this, the double spiral microchannel was dimensionally designed to have 
a 406 mm length (L), 300 µm width (W), and 15 µm height (H) with six spiral loops for each 
direction (Fig 4.2). Our work is the first to accomplish hydrodynamic separation and capture of 
bacteria and endotoxin in a curved geometry. The double spiral microchannel described has a 
low aspect ratio (H/W = 0.05). The low aspect ratio of the microchannel rapidly forces particles 
and bacteria to migrate to final equilibrium positions.  
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Figure 4.2. Double spiral microfluidic design to maximize bacterial separation efficiency.  a, 
Fabricated PDMS microfluidic device consisting of two, 6-loop spiral microchannels joined at the 
S-junction to form a double spiral channel with one inlet and one outlet for particle/bacterial cell 
separation. b, CAD drawing of the double spiral fluidic module employed to create the master 
mold. 
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Materials and Methods 
Synthesis of Colistin-PEG-Silane ligand 
NHS-PEG-Silane (N-Hydroxysuccinimide-Polyethylene glycol1000-Silane, Nanocs, Inc., 
Lot #160429) (30 mg mL-1) was dissolved in ethanol/water, pH 5 (50/50 v/v%, pH adjusted with 
acetic acid). 35 mg mL-1 of colistin sulfate (Sigma-Aldrich, Lot #SLBN5158V) was added to the 
NHS-PEG-Silane solution. The solution was vortexed for 30 seconds and then allowed to react 
at 21°C for 2 h. NHS was used to couple a heterobifunctional NHS-PEG-Silane linker to one of 
the five similarly reactive L-α-diaminobutyric acid (Dab) residues of colistin, resulting in Colistin-
PEG-Silane59–61,73. 
PEG-Silane ligand solution preparation 
PEG-Silane (Polyethylene glycol1000-Silane, Nanocs, Inc., Lot #160706OH) (30 mg mL-1) 
was dissolved in ethanol/water, pH 5 (50/50 v/v%, pH adjusted with acetic acid). The solution was 
vortexed for 30 seconds and then allowed to incubate at 21°C for 2 h. 
Design and fabrication of device 
In designing the proposed double spiral microfluidic device, the effects of Dean drag and 
the lift forces were accounted for. The spiral geometry in this design was formulated to cause 2 
μm particles (ap) to occupy a single equilibrium position near the microchannel inner wall at a flow 
rate of 0.2 mL/min. To accomplish this, the microchannel was designed to be 300 μm wide and 
15 μm high (ap/h ∼0.13). 
Microchannel hydraulic diameter, Dh, was calculated as follows 
𝐷 = 	 2𝑤ℎ(𝑤 + ℎ) = 	2.857EW8	m																																																													(4.1) 
where w is the channel width (300 μm) and h is the channel height (15 μm). The average fluid 
velocity, Uf, at the desired volumetric flow rate of 3.33E-9 m3/s is calculated as follows 
𝑈p = 𝑄𝐴 = 	3.33𝐸W\	𝑚/𝑠4.5𝐸W\	𝑚P = 0.74	𝑚 𝑠 																																																	(4.2) 
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where A is the vertical cross sectional area (width * height) of the channel. The magnitude of the 
secondary Dean flows, De, can now be solved142: 
𝐷𝑒 = 	𝜌𝑈p𝐷𝜇 𝐷2𝑅 = 0.285																																																																(4.3) 
where ρ is the density of fluid (ρblood = 1060 kg m−3), μ is the fluid viscosity (μblood = 3*10−3 kg m−1 
s−1), and R is the radius of curvature (0.0098 m) of the convex surface of the channel path. 
Depending on particle size, channel geometry, and flow rate, transverse secondary Dean flows 
can entrap particles in one of the two Dean vortices. Assuming Stokes drag, the Dean drag force, 
FD, exerted on particles due to these flows can be calculated: 𝐹 = 5.4 ∗ 10W7𝜋𝜇𝐷𝑒9.]𝑎																																																									(4.4) 
where ap is the particle diameter. In addition to FD, the particles also experience a net lift force 
(FL), which is a combination of shear induced inertial lift forces and wall induced lift forces. 
Asomolov et al. derived an equation for net inertial lift force that takes into account both shear-
induced and wall-induced lift forces136: 𝐹e = 	𝜌𝐺P𝐶e𝑎7																																																																					(4.5) 
 where G is the shear rate of the fluid (s−1) and CL is the lift co-efficient as a function of the particle 
position across the channel cross-section. The shear rate of the fluid, G, is given by G = Umax/Dh. 
Umax is the maximum fluid velocity (m s−1) and can be approximated as 2Uf142.  CL is assumed to 
have an average value of 0.5144,145. If the Dean drag force acting on the particles is less than the 
corresponding net lift force, then the lift force dominates and the particles equilibrate. A summary 
of the magnitude of the forces imposed on 2 μm, 5 μm and 10 μm particles using the described 
fluidic device is shown in Table 4.1. 
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Table 4.1. Summary of Dean drag force (FD) and the net lift force (FL) acting on 2, 5 and 10 μm 
particles at 0.2 mL/min. 
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To achieve complete focusing of the 2 μm particles, it is also essential to determine the 
length of the spiral microchannel needed for the 2 μm particles to focus into a stream prior to 
reaching the channel outlets. The expression for particle lateral migration velocity (UL) is136 
𝑈e = 	𝜌𝑈;UVP 𝑎𝐶e3𝜋𝜇𝐷P 																																																																			(4.6) 
The channel length (LI) needed for the particles to streamline and focus is described by 
𝐿 = 	𝑈p𝑈e ∗ 𝐿T																																																																						(4. 7) 
where LM is the migration length (m), or approximately one half of the channel width (150 μm). 
The calculated values of LI are shown in Table 4.2. 
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Table 4.2. Summary of necessary channel length for focusing (LI). 
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The double spiral channel length must be sufficiently long in order to satisfy the condition of LI, 
thereby allowing formation of a single ordered stream of 2 μm particles along the channel wall 
prior to reaching the outlet region. The length of the double spiral microchannel was fixed at 
0.406m.  
The microfluidic device pattern was designed and drawn in AutoCAD software (AutoCAD 
2014, AutoDesk, Inc.). The design consisted of a 6-loop double spiral microchannel with one inlet 
and one outlet. The microchannel rotates clockwise for 6 loops, changes direction through the S-
junction, then rotates counterclockwise to form the double spiral. The double spiral microchannel 
has dimensions of 406 mm L, 300 µm W, and 15 µm H. The spacing between two adjacent loops 
is 500 µm. The outermost radius of curvature is 9.8 mm. Standard photolithographic techniques146 
were used to generate a mold from a silicon master that was spin coated with a SU8-2010 
(MicroChem Corp.) layer (WS-400 Lite Series Spin Processor, Laurell Technologies Corp.) on a 
4-inch silicon wafer (Nova Electronic Materials). After soft baking at 95 °C for 5 minutes, the SU-
8 layer was patterned using a mask aligner (MJB 3 Mask Aligner, Suss MicroTech) with a UV light 
(Novacure 2100, Exfo Inc.) and a negative photomask (Infinite Graphics, Inc.). After subsequent 
post-exposure bake steps at 95 °C for 5 min, the wafer was developed using SU-8 developer 
(MicroChem Corp.). A final hard bake was performed for 5 min at 150 °C. The wafer was used as 
the master mold to cast the microfluidic channels.  Degassed PDMS (polydimethylsiloxane, mixed 
in a 10:1 ratio of PDMS base with curing agent, Sylgard 184, Dow Corning Inc.) was cast over 
the mold and baked at 65 °C for 4 h in an oven. The PDMS with embedded channels was 
subsequently cut by razor blade and removed from the master mold. One inlet and one outlet 
were punched through the PDMS using a 1.5 mm biopsy punch (Integra Miltex). The PDMS slab 
was then bonded to a glass substrate (43 mm X 50 mm, Ted Pella, Inc.) post oxygen plasma 
treatment (PDC-001 Plasma Cleaner, Harrick Plasma). Immediately following plasma treatment 
and bonding to the glass cover slip, 1/16” O.D. tygon microbore tubing (Cole Parmer Corp.) was 
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inserted through both the inlet port and outlet port. Colistin was tethered to the double spiral 
microfluidic device channel walls using the Colistin-PEG-Silane linker and silane chemistry 
(Appendix B Fig B1)147. Colistin-PEG-Silane solution was flowed through the oxidized PDMS 
microchannel using a 1 mL luer-lock disposable syringe (Becton Dickinson). The Colistin-PEG-
Silane solution was allowed to contact the microchannel surface for 30 min at 65 °C, according to 
well established silanization principals148. Use of the heterobifunctional Colistin-PEG-Silane linker 
was designed to enable colistin decoration of the microchannel walls with a PEG molecular spacer, 
which was intended to reduce steric hindrance of colistin interactions with bacteria and endotoxin. 
In the range of physiological pH values, the primary amine groups of colistin are protonated, and, 
therefore, positively charged63,64. The positive charge of colistin allows for binding to the 
negatively charged outer membrane of Gram-negative pathogens and endotoxin42. PEG-Silane 
functionalized devices were also synthesized using a very similar approach, and used as a 
PEGylated control group that lacked colistin decoration. No ligand was added to result in non-
functionalized double spiral microfluidic devices. 
Confirmation of colistin conjugation to microchannel walls 
Fluorescent labeling of colistin within the colistinated double spiral microfluidic device was 
performed using ATTO 488 NHS ester (Sigma-Aldrich, Lot #BCBQ4012V). ATTO 488 NHS ester 
(2 mg mL-1) was dissolved in dimethylsulfoxide (DMSO, Sigma-Aldrich) immediately prior to use. 
Labeling was carried out by adding the fluor to the colistinated microchannel, followed by 
incubation for 30 minutes at room temperature. The stained microchannel was then washed with 
phosphate buffer saline (PBS, Gibco, Lot #1806048), pH 7.4. The same protocol was used on the 
PEGylated microchannel as a control. The fluorescently stained microchannels were then imaged 
using a fluorescent microscope (EVOS FL, Invitrogen). Image-J software was used to quantitate 
the fluorescent intensity across the channel width of captured images. Dilutions of ATTO 488 NHS 
ester within non-functionalized microfluidic devices were used as references to generate an ATTO 
488 NHS ester standard fluorescence calibration curve. The fluorescence intensity of the 
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colistinated microchannel and the PEGylated microchannel were compared to that of the ATTO 
488 NHS ester standard curve, which allowed for quantification of the number of colistin 
molecules per double spiral microchannel. 
Colistin retention  
The possibility of Colistin-PEG-Silane ligand disassembly from the surface of the double 
spiral microfluidic device under flow conditions was evaluated using MaxSignal® Colistin enzyme-
linked immunosorbent assay (ELISA) test kit (BIOO Scientific, Lot 
#109501081415$626311708249). PBS, pH 7.4, was flowed through the colistinated double spiral 
microfluidic device at 0.2 mL min-1 for 2 h. Sample was collected from the device outlet at various 
time points (1, 2, 4, 5, 10, 20, 30, 45, 60, 120 minutes) for analysis.  Total colistin content in each 
sample was quantified by the colistin ELISA according to the manufacturer's instructions. 
Absorbance was measured at 450 nm using a microtiter plate reader, and these values were used 
to calculate the colistin concentration in the samples according to the calibration curve (assay 
detection range, 0.5 to 50 ng/ml). Results from colistin ligand retention characterization prompted 
the washing of each double spiral microfluidic device continuously for 30 minutes with 70% 
ethanol prior to experimental use, resulting in negligible colistin release during the capture studies.   
Microbial culture 
Bacterial cultures (i.e., Acinetobacter baumannii ATCC17978, Colistin-resistant 
Acinetobacter baumannii 19606R58, Colistin-resistant Acinetobacter baumannii ‘Patient 2’149, 
Klebsiella pneumoniae ATCC700603, Bacillus subtilis 1A578 (Bacillus Genetic Stock 
Center)150,151, Staphylococcus aureus ATCC29213) were plated on LB agar (Sigma-Aldrich, Lot 
#SLBR1403V) and grown overnight at 37 °C. Single colonies of each strain were then inoculated 
in LB broth (1X) (Gibco, Lot # 1803272) and grown at 37 °C, shaking at 150 rpm. Cell 
concentrations were measured with OD595 spectrometry (Infinite F500, Tecan). 
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Inertial focusing visualization 
Two types of polystyrene microspheres (Spherotech Inc.) with mean diameters of 10.2 μm 
± 4 μm and 2 μm ± 0.3 μm were used to analyze particle focusing within the microchannel. 
Suspensions were provided at 1% w/v with 1 vol% of Tween-20 surfactant (Sigma-Aldrich) to 
prevent particle aggregation. Equal volumes of two suspensions were diluted to 0.1% w/v using 
de-ionized (DI) water. The fluorescent particles were individually introduced into the non-
functionalized double spiral microchannel at 0.2 mL min-1 using an infusion syringe pump (Nexus 
3000, Chemyx Inc.) connected to the input port of the microchannel through a 1 mL luer-lock tip 
syringe and 1/16” O.D. tygon inlet tubing. Particle trajectories and focusing within the double spiral 
channel were visualized in real-time using fluorescence microscopy (EVOS FL, Invitrogen).  This 
process was repeated using SYTO®9 green fluorescent nucleic acid labeled (5 mM solution in 
DMSO, Molecular Probes, Lot #1687876A) A. baumannii ATCC17978. After a 5-minute 
incubation with SYTO® 9, the bacteria were washed three times with RNase-free, ultrapure water 
(USB Corp., Lot #4235512) and resuspended to a concentration of ~8 X 107 colony forming units 
(CFUs) mL-1. The fluorescently labeled bacteria suspension was flowed through a PEGylated 
double spiral microfluidic device at 0.2 mL min-1 using an infusion syringe pump. Bacterial 
trajectories and focusing within the double spiral channel were visualized in real-time using 
fluorescence microscopy (EVOS FL, Invitrogen).   
Susceptibility Testing 
Colistin minimum inhibitory concentrations (MIC) of bacterial strains were confirmed by 
standard agar dilution methods152.  Results were interpreted according to the Clinical and 
Laboratory Standards Institute susceptibility breakpoints153.  
Bacterial capture visualization 
A. baumannii ATCC17978 was labeled with SYTO®9 as previously described in the 
‘inertial focusing visualization’ methods section. The fluorescently labeled bacteria suspension 
was flowed through the colistinated and PEGylated double spiral microfluidic devices at 0.2 mL 
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min-1 using an infusion syringe pump. The devices were then washed four times with PBS, pH 
7.4, to remove any weakly bound bacteria. Fluorescent images of the microchannels were 
obtained using fluorescence microscopy (EVOS FL, Invitrogen). This process was repeated using 
fluorescently labeled A. baumannii ATCC17978 and S. aureus ATCC29213 spiked into EDTA-
anticoagulated, whole human blood. Human blood was obtained from healthy donors with 
informed consent in accordance with the Vanderbilt University Human Subjects Institutional 
Review Board (IRB) (protocol number 111251).    
Bacterial capture quantification 
Testing of the pathogen-capture capacity of the colistinated and PEGylated double spiral 
microfluidic devices were carried out by first adjusting an A. baumannii ATCC17978 bacterial 
suspension to ~8 X 107 CFUs mL-1 in PBS, pH 7.4. A concentration of ~102 CFUs mL-1 was 
obtained by serial dilution of the initial suspension, which served as the control. Bacterial samples 
were infused through the colistinated double spiral microfluidic device at 0.2 ml min-1, and samples 
were collected from the device outlet at 5 different time points (1, 2, 3, 4 and 5 minutes). This 
process was also repeated for the PEGylated double spiral microfluidic device. The recovered 
solutions from the outlet of the double spiral microfluidic devices were diluted in the same fashion 
as the control group.  The collected samples and control were plated on LB-agar Petri dishes in 
triplicate (100 μL) for quantitating pathogen-capture capacity. Plates were incubated at 37 °C for 
24 h, and colonies formed on the Petri dishes were counted. The number of the initial and 
recovered bacteria were calculated by multiplying the average number of colonies counted from 
the replicates by their respective dilution factor. The number of captured bacteria was determined 
by subtracting the number of recovered bacteria from the initial amount of bacteria (i.e. untreated 
control group). The capture capacity was calculated by dividing the number of captured cells by 
the number of initial cells. Capture capacity of the following bacterial strains in PBS, pH 7.4 was 
quantified: A. baumannii ATCC17978, colistin-resistant A. baumannii 19606R, colistin-resistant 
A. baumannii ‘Patient 2’, K. pneumoniae ATCC700603, and B. subtilis 1A578. This process was 
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also repeated for A. baumannii ATCC17978 spiked into EDTA-anticoagulated, whole human 
blood.   
Endotoxin binding assay 
The Pierce LAL Chromogenic Endotoxin Quantification kit (Thermo Scientific, Lot # 
RG236327) was used according to the manufacturer’s protocol to quantify the endotoxin capture 
capacity of the colistinated and PEGylated double spiral microfluidic devices, respectively. Briefly, 
Escherichia coli (E. coli) Endotoxin Standard (011:B4) was reconstituted in endotoxin-free water 
at a concentration of 1 EU mL-1 (Endotoxin Unit) and the solution was flowed through the 
colistinated double spiral microfluidic device at 0.2 ml min-1 using an infusion syringe pump. 
Samples were collected from the device outlet at 5 different time points (1, 2, 3, 4 and 5 minutes). 
This process was repeated for the PEGylated double spiral fluidic device. Collected samples were 
then analyzed for endotoxin concentration according to the manufacturer’s protocol, and results 
were read at 450 nm.  
Hematology studies 
To determine whether treatment with the double spiral microfluidic device significantly 
changes blood hematologic parameters, 1 mL of EDTA-anticoagulated whole, human blood was 
collected from the colistinated device outlet after being flowed through the blood-cleansing device 
at 0.2 ml min-1. This process was repeated for the PEGylated device. Red blood cell lysis was 
then analyzed to determine release of free hemoglobin in plasma. Plasma hemoglobin was 
measured by according to well-established protocols57. Following passage through the device, 
the blood samples were centrifuged (500 x g) and the supernatant was spectrophotometrically 
analyzed for hemoglobin release using a plate-reader (Tecan, Infinite M1000 Pro) at 451 nm in 
order to determine percent hemolysis relative to the Triton-X positive control. Triton X-100 (Sigma-
Aldrich) was diluted in diH2O to result in a 20 v/v % Triton-X detergent concentration, which served 
as the positive control. The negative control used was EDTA-anticoagulated whole, human blood 
that was not flowed through a double spiral microfluidic device (i.e. untreated). Percent of 
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hemoglobin release was calculated according to the following equation: Hemoglobin release (%) 
= [(Sample451nm – Negative control451nm)/(Positive control451nm – Negative control451nm)] X 100%. 
Complete blood counts of each sample (i.e. untreated, colistinated device, PEGylated device) 
were performed by the Vanderbilt University Translational Pathology Shared Resource Core.  
Device scale-up 
A larger version of the initial double spiral microfluidic device was fabricated and 
functionalized using the previously described methods. The scaled-up version of the device 
consisted of a 4-loop double spiral microchannel with one inlet and one outlet. Dimensions of the 
scaled-up version were 323 mm L, 750 µm W, and 15 µm H. The spacing between two adjacent 
loops was 500 µm and the radius of the outermost curvature was 11.2 mm. The dimensions of 
the scaled-up device were adjusted such that the volume:surface area ratio was comparable to 
that of the initial device design.  The bacterial capture capacity of the scaled-up device was 
characterized to compare the capture capacity to that of the smaller device.  The ‘bacterial capture 
quantification’ assay using the scaled-up device was performed with A. baumannii ATCC17978. 
Statistical analysis 
All measured values are reported as an average mean of at least triplicate samples ± 
standard deviation (SD), as indicated by error bars. Significant differences were determined using 
a one-way ANOVA followed by post hoc Tukey’s multiple comparison test, as defined by P values 
< 0.01. 
 
Results and Discussion 
Colistin conjugation to microchannel walls 
Fluorescent labeling and stoichiometric analysis were used to estimate that 1.76 µg of 
colistin was functionalized along the walls of the colistinated double spiral device (Appendix B Fig 
B2). The amount of colistin associated with the surface of this device is non-toxic to humans59,68,73. 
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An ELISA was performed to estimate the amount of colistin-containing molecules that were 
released from the double spiral microfluidic device. Continuous flow for 2 hours resulted in 
approximately 300 ng of colistin release from the channel (Appendix B Fig B3). 
Inertial particle focusing in the double spiral microfluidic device 
Fluorescent polystyrene microparticles under continuous flow conditions were imaged 
within the non-functionalized double spiral microfluidic channel. At a volumetric flow rate of 0.2 ml 
min-1, with corresponding Re = 14.9, 2 μm sized particles were focused near the inner wall of the 
microchannel (Fig 4.3a), while 10.2 μm size particles were focused near the center of the 
microchannel width (Fig 4.3b). The composite fluorescence images show the trajectories of the 
10.2 μm (red stream) and 2 μm particles (green stream), with the larger particles approximating 
the trajectory of larger blood cells (i.e. red blood cells and white blood cells). Microparticles are 
inertially focused at equilibrium positions as a function of diameter. A clear separation of bacterial-
sized particles from blood cell-sized particles is evident. A. baumannii ATCC17978 are inertially 
focused even closer to the channel wall than 2 μm diameter spherical particles. In addition, 
bacteria appear near both lateral surfaces of the double spiral device. These behaviors are in 
agreement with the inertial design as derived from net inertial lift force (FL) and Dean drag force 
(FD). 
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Figure 4.3. Microparticle and bacterial focusing within double spiral microchannel. Images were 
acquired within the double spiral microchannel at a continuous flow rate of 0.2 mL min-1. a, 
Focusing of 2 µm particles (green) within the double spiral microchannel. b, Focusing of 10 µm 
particles (red) within the double spiral microchannel. c, Labeled A. baumannii ATCC17978 
(green) focusing along the inner and outer walls of the double spiral microfluidic device c, Labeled 
A. baumannii ATCC17978 (green) focusing along the inner and outer walls of the double spiral 
microfluidic device.  
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Bacterial cell capture using surface-modified double spiral microfluidic device 
A. baumannii ATCC17978 bacterial cells were chosen as the standard specimen for 
qualitatively and quantitatively evaluating the bacterial capture capacity of the colistinated and 
PEGylated double spiral microfluidic devices. Green, fluorescently labeled A. baumannii 
ATCC17978 are bound to the colistinated microchannel walls following passage through the 
microfluidic device at 0.2 mL min-1 and subsequent washing (Fig 4.4a and 4.4b). However, 
significant bacterial capture did not occur within the PEGylated double spiral microfluidic device, 
presumably due to the absence of colistin surface functionalization (Fig 4.4c). 
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Figure 4.4. Fluorescently labeled bacteria captured along colistinated microchannel walls. a & b, 
Fluorescent images displaying A. baumannii ATCC17978 (green) captured within colistinated 
microfluidic device following washing. c, Fluorescent image displaying the lack of A. baumannii 
ATCC17978 capture within the PEGylated microfluidic device following washing. 
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Bacterial capture capacity was quantified by flowing 1 mL of A. baumannii ATCC17978 
suspension in PBS, pH 7.4, through the microfluidic devices at a flow rate of 0.2 mL min-1. A 
bacterial cell capture capacity of over 107 CFUs was achieved with a single passage through the 
colistinated double spiral microfluidic device (Fig 4.5a), as confirmed by the reduction of colonies 
that could be cultured from the fluid exiting the device. K. pneumoniae ATCC700603, another 
Gram-negative human pathogen, was also successfully removed from flowing fluid (Fig 4.5b). 
The colistinated double spiral microfluidic device also captured and removed antibiotic-resistant 
organisms, including colistin-resistant A. baumannii ‘Patient 2’149 and colistin-resistant A. 
baumannii 19606R58, from flowing fluid (Fig 4.5c and 4.5d). These colistin-resistant strains are 
well characterized in literature and colistin-resistance was reconfirmed through MIC assessment 
(Appendix B Table B1). Binding of green fluorescent A. baumannii ATCC17978 to the colistinated 
double spiral microchannel device was strongly supported by PEG functionalization (Fig 4.5a – 
4.5d).  Colistinated and PEGylated devices did not capture Gram-positive B. subtilis 1A578, 
confirming specificity for Gram-negative pathogens in colistin-functionalized devices (Appendix B 
Fig B4). 
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Figure 4.5. Quantification of bacterial capture capacity. Pathogen capture capacity of Gram-  
negative bacterial isolates when spiked into PBS and flowed through the colistinated and 
PEGylated double spiral microfluidic devices at 0.2 ml min−1. a, A. baumannii ATCC17978. b, K. 
pneumoniae ATCC700603. c, Colistin-resistant A. baumannii ‘Patient 2’. d, Colistin-resistant A. 
baumannii 19606R. Results are plotted as the mean ± SD, n = 3. *P < 0.01. 
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Extracorporeal blood cleansing 
The blood-cleansing capability of the double spiral microfluidic device was assessed using 
fresh, whole human blood that was EDTA-anticoagulated and experimentally contaminated with 
A. baumannii ATCC17978.  A single colistinated double spiral microfluidic device removed 
approximately 107 colony forming units of bacteria from whole blood with one pass through the 
device at a flow rate of 0.2 ml min−1 (Fig 4.6a). Bacterial cell capture from flowing blood was also 
confirmed using fluorescence microscopy. Green, fluorescently labeled A. baumannii 
ATCC17978 is bound to the colistinated microchannel walls following passage of infected blood 
through the microfluidic device at 0.2 mL min-1 and subsequent washing (Fig 4.6b and 4.6c). 
Gram-positive S. aureus ATCC29213 spiked in whole, human blood, however, did not bind to the 
colistinated microchannel walls, confirming specificity for Gram-negative pathogens in the colistin-
functionalized devices (Fig 4.6d). Flowing whole, human blood through the colistinated and 
PEGylated double spiral microfluidic devices had no detectable effect on blood composition 
(Appendix B Table B2), nor did it induce red blood cell hemolysis (Appendix B Table B3).  
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Figure 4.6. Ex vivo blood cleansing using the double spiral microfluidic device. a, Capture 
capacity for A. baumannii ATCC17978 when spiked into whole, human blood and flowed through 
the colistinated and PEGylated double spiral microfluidic devices at 0.2 ml min−1. Results are 
plotted as the mean ± SD, n = 3. *P < 0.01. b & c, Green fluorescently labeled A. baumannii 
ATCC17978 capture from whole, human blood following passage through colistinated double 
spiral microchannel at 0.2 mL min-1 and subsequent washing. d, Lack of green fluorescently 
labeled S. aureus ATCC29213 capture following passage through a colistinated double spiral 
microchannel at 0.2 mL min-1, confirming specificity for Gram-negative pathogens in the colistin-
functionalized devices.  
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Total bacterial capture capacity 
The colistinated double spiral microfluidic device removed ~107 CFUs of live A. baumannii 
ATCC17978 (Fig 4.5a) and a similar quantity of K. pneumoniae ATCC700603 (Fig 4.5b) from 
PBS within 5 minutes of device operation. In addition, colistin-resistant strains of A. baumannii 
(i.e. A. baumannii 19606R and A. baumannii ‘Patient 2’) were captured with equal efficacy as the 
wild-type, colistin sensitive A. baumannii strain (Fig 4.7). Statistical analysis confirmed that the 
colistinated double spiral microfluidic device captured Gram-negative bacteria from whole, human 
blood at a capacity that is not significantly different than in PBS (Fig 4.7).  
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Figure 4.7. Total bacterial capture capacity of colistinated double spiral microfluidic device. The 
maximum bacterial load that a single colistinated double spiral fluidic device can capture is 
reported with respect to each bacterial strain indicated. A. baumannii ATCC17978 spiked in PBS 
served as the control. Capture of A. baumannii ATCC17978 was significantly different than the 
capture of B. subtilis 1A578. However, the capture of A. baumannii ATCC17978 was not 
significantly different than any other bacterial isolate listed. The maximum capture capacities of 
all other bacterial isolates listed (K. pneumoniae ATCC700603, A. baumannii 19606R, A. 
baumannii ‘Patient 2’, and A. baumannii ATCC17978 in blood) were also significantly different 
that of B. subtilis 1A578. Data were compared using one-way ANOVA followed by post hoc 
Tukey’s multiple comparison test. Results are plotted as mean ± SD, n = 3. *P < 0.01. 
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Quantification of endotoxin capture 
Endotoxin, one of the principal components of the outer membrane of Gram-negative 
bacteria, also contributes to the systemic inflammatory response that is characteristic of sepsis154. 
Therefore, the removal of endotoxin from flowing fluid using the double spiral microfluidic device 
was assessed. Endotoxin was spiked into endotoxin-free water and continuously flowed through 
the device at 0.2 mL min−1 for 5 minutes, totaling 1 mL. Endotoxin was rapidly captured from the 
fluid passing through the colistinated double spiral microfluidic device, with endotoxin capture 
efficiency approaching 100% in single pass operation (Appendix B Fig B5). In contrast, endotoxin 
was not effectively captured using the PEGylated device, demonstrating the critical requirement 
for colistin in endotoxin retention in the double spiral. 
Device scale-up for clinical translation 
The capture capacity of the described colistinated double spiral microfluidic device is 
approximately 107 CFUs (Fig 4.7), which exceeds the requirements to treat a septic patient by 
more than two orders of magnitude118–120. However, for potential clinical translation, the flow rate 
associated with the current device design must be increased to enable treatment of larger animal 
models and humans. Therefore, a larger version of the double spiral fluidic design was developed 
to demonstrate the feasibility of scaling up the current design. The scaled-up version of the 
colistinated double spiral microfluidic device, operating at a flow rate three times greater than that 
used with the initial design, captured of over 107 A. baumannii ATTC17978 CFUs in single pass 
operation (Fig 4.8). Dimensions of the scaled-up device were selected to provide a volume to 
surface area ratio similar to that of the original device, while maintaining appropriate 
hydrodynamic particle focusing characteristics. The governing principles of fluid transport in 
closed conduits can be used to design a larger double spiral device with performance 
characteristics appropriate for increased treatment volumes. 
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Figure 4.8. Bacterial capture capacity of larger double spiral microfluidic device.  A. baumannii 
ATCC17978 spiked into PBS was flowed through larger colistinated and PEGylated double spiral 
microfluidic devices (328 mm L  X 750 µm W  X 15 µm H) at 0.6 mL min-1. The A. baumannii 
ATCC17978 capture capacity of the microfluidic device was quantified over the time indicated. 
Results are plotted as the mean ± SD, n = 3. *P < 0.01. 
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Asymmetric spiral-based microfluidic devices have previously been designed to achieve 
equilibration of large (>10 μm) microparticles31,135,155. This work is the first to successfully 
demonstrate the equilibration of 2 μm sized particles under continuous flow conditions within a 
double spiral microchannel. Figure 4.3a and 4.3b demonstrate that 2 μm particles (ap/H
 
~ 0.13;  
FL > FD) and 10.2 μm particles (ap/H
 
~ 0.67;  FL > FD) are more influenced by inertial lift forces 
rather than Dean force, and thus equilibrate within the microchannel. These results are in 
agreement with the work by Kuntaegowdanahalli and Bhagat, validating that particles that satisfy 
ap/H ≥ 0.07 are able to focus and occupy a single equilibrium position within a microchannel 31,155. 
The low aspect ratio of the channel design is believed to promote the focusing of smaller particles 
near the inner channel wall32. The larger 10 μm sized particles equilibrate near the center of the 
channel due to the larger wall-induced lift force experienced, in comparison to 2 μm 
particles32,142,156. 
Focusing positions of non-spherical particles are dependent on the particle’s largest cross-
sectional dimension157,158. A. baumannii ATCC17978, a rod-shaped (coccobacillus) bacterium, is 
typically 2 μm in length and 0.5 μm in width73. Hence, 2 μm particle focusing was evaluated (Fig 
4.3a). However, non-spherical bacterial cells can freely rotate and experience strong rotational-
induced lift forces while being inertially focused and sorted. At Reynolds numbers greater than 
10, both spherical and rod-shaped particles generally follow the same focusing trend159. However, 
in microchannels with a low aspect ratio, such as the case with this design, rod-shaped particles 
focus to two equilibrium regions, one along the inner microchannel wall and the other along the 
outer microchannel wall160, as experimentally confirmed (Fig 4.3c). Bacteria oscillate when close 
to the channel wall due to the rotational forces imposed on the rod-shaped particles161. Near-wall 
focusing combined with rotation inducing lift forces presumably allow for direct contact of bacteria 
with both the inner and outer colistin functionalized microchannel walls.  
The requirement for colistin functionalization suggests that wild-type A. baumannii capture 
is mediated by colistin (Fig 4.4, Fig 4.5a and 4.5b). The colistin-dependent capture of two 
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independently isolated A. baumannii strains that are strongly colistin resistant implies a previously 
unrecognized approach for the capture and removal of antibiotic-resistant bacteria (Fig 4.5c and 
4.5d). This result is consistent with colistin-resistance as independent of colistin binding to the 
bacterial outer membrane. These colistin-resistant strains have increased expression of many 
genes involved in cell envelope and membrane biogenesis58. The inability of colistin functionalized 
double spiral devices to capture Gram-positive bacteria, such as B. subtilis 1A578, further 
supports the capture mechanism as colistin recognition since Gram-positive bacteria are 
insensitive to, and unable to bind, colistin.  
Robust bacterial capture from blood is essentially identical to that for blood cell-free 
bacterial suspensions in vitro (Fig 4.6 and 4.7). The design of the double spiral spatially isolates 
the formed elements of the blood from the regions where bacterial binding occurs and is 
hypothesized to be responsible for bacterial capture efficiency that is not reduced in the presence 
of blood cells. The simplicity and robustness of this design supports the translational potential of 
the approach.  
Use as a treatment modality in sepsis demands both increased flow capacity to 
accommodate the blood volume of larger living systems and a way to isolate Gram-positive 
bacteria. We demonstrate here the potential for scale-up using the same quantitative approach 
and design principles applied to the original device (Fig 4.8). A. baumannii capture occurs with 
equal effectiveness after increasing the cross-sectional area of the fluidic device while holding the 
volume to surface area ratio constant. Importantly, this proof of concept is easily expandable to 
include devices possessing capture agents for Gram-positive bacteria134. Combination devices 
will, presumably, offer the capability to remove bacteria regardless of presentation as Gram-
positive, Gram-negative, or antibiotic resistant, thus enabling early treatment in the absence of 
positive bacterial culture or strain identification from a blood sample. Furthermore, the removal of 
bacteria and endotoxin offers a greatly needed, new approach for the treatment of sepsis. 
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Conclusions 
This work describes a double spiral microfluidic device, which can separate and capture 
A. baumannii from whole blood continuously with a maximum bacterial capture capacity of 
approximately 107 CFUs. Compared to current sepsis therapies, such as antibiotic administration 
or immunomodulatory therapies, the double spiral fluidic platform has distinct advantages, 
including avoidance of clogging through size-based cell separation, an effective capture capacity, 
and removal of multi-drug resistant infections. This is the first device optimized specifically for 
size-based separation of bacteria from blood. The fluidic platform also eliminates the need for 
complex external force fields, making the device easy to fabricate and implement. Mechanically 
removing bacteria and endotoxins breaks the current paradigm of sepsis therapy that is focused 
on applying antibiotics following bacterial culture and identification. Continued development of this 
technology will enable use as an adjuvant sepsis therapy and provide a more streamlined path to 
clinical translation. 
 
Summary 
Removal of bacteria and endotoxin from blood could potentially be a valuable adjunct to 
antibiotics for the treatment of sepsis. However, the separation of pathogens from blood is 
generally challenging, since non-spherical bacterial cells and endotoxins cannot be easily 
removed by common filtration methods, such as pore-based hemoperfusion filters, without 
significant complication. We demonstrate that an inertial-based microfluidic device conjugated 
with a bacterial- and endotoxin-targeting ligand exhibits significant blood cleansing capabilities. 
The device described herein eliminates pathogens, including multi-drug resistant strains, from 
whole, human blood. The bacterial load captured by the compact, inertial-based microfluidic 
device exceeds the maximal bacterial load in septic patients by more than two orders of 
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magnitude.  These results provide the first proof-of-principle that extracorporeal extraction of 
pathogens and endotoxins using inertial-based fluidics may be used as a next-generation 
purification technology to reduce sepsis-associated morbidity and mortality. This work 
successfully fulfills Specific Aim 3 of this dissertation. 
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CHAPTER V 
 
SYNOPSIS AND CONCLUSIONS 
The goal of my dissertation work was to develop a transformative fluidic platform for 
removal of Acinetobacter baumannii, a leading cause of sepsis worldwide, from flowing fluids. In 
order to develop this fluidic platform, I overcame a number of hurdles. Initially, I planned to use 
magnetic nanoparticles for the capture and removal of A. baumannii from fluid. However, through 
computational modeling I discovered that this approach presented many complications due to the 
magnetophoretic separation limitations imposed by magnetic nanoparticle-pathogen complexes. 
Nevertheless, I was able to develop a colistin functionalized nanoparticle that allowed for binding 
of A. baumannii in a saline solution. This work demonstrated that colistin could be used as an A. 
baumannii-targeting motif. Based on this knowledge, I proceeded to develop a colistin 
functionalized fluidic platform for the separation and capture of A. baumannii from flowing fluids. 
The design of the colistin functionalized fluidic platform was informed by my previously developed 
computational model of sepsis progression.  
As outlined in the chapters of this dissertation, I began by developing a novel colistin 
functionalized nanoparticle for the rapid capture of A. baumannii (Chapter II). My work detailed in 
Chapter II was published in the Journal of Biomedical Nanotechnology73.  I demonstrated for the 
first time the power of incorporating colistin-modified nanoparticles for capture of multiple Gram-
negative bacterial strains, including drug resistant variants. The ability to control the surface 
coverage of colistin functionalized nanoparticles played an important role in efficient capture of 
the bacteria. I also discovered that extending the colistin probe from the surface of the 
nanoparticles with a polyethylene glycol spacer provided greater ligand flexibility, presumably 
allowing the colistin ligand to adopt orientations more amenable to effective interactions with the 
targeted pathogen surface. Importantly, the time required for pathogen capture was significantly 
less than nanoparticle-pathogen capture times found in previously published literature. I 
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demonstrated that colistin enabled nanoparticle complexation with A. baumannii rapidly, reaching 
half-maximum saturation in approximately 7 minutes. This rate of capture is significantly faster 
than the most advanced nanoparticle-pathogen extraction platforms reported to date26,134. These 
results demonstrate that colistin is an excellent molecular probe for use in bacterial capture 
assays, where the stability, reaction conditions, and control of ligand orientation are more flexible 
than those for typical antibody-based strategies. I also demonstrated that a single colistin 
functionalized nanoparticle can be used to target and isolate a variety of Gram-negative 
pathogens, including colistin-resistant variants. Thereby, negating the requirement of pathogen 
identification prior to isolation and removing the need of nanoparticles that target a specific 
bacteria strain or variant. 
Following the development of a colistin-based bacterial targeting ligand, I developed a 
computational model to assess the bacterial extraction characteristics required for effective 
eradication of infection (Chapter III). My work detailed in Chapter III was published in PLOS ONE27.  
The engineering-based mathematical model that I developed was used to quantitatively describe 
the kinetics of pathogenesis and progression of sepsis under various conditions, including 
bacterial separation therapy, to better understand disease mechanisms and quantitatively assess 
the biological impact of bacterial separation therapy. I discovered from this model that mechanical 
bacterial separation from blood has the potential to reduce the time of total bacteria clearance 
from the blood of an immunocompromised subject by 49%, compared to antibiotic treatment alone. 
The time required for bacteria clearance from the lungs, spleen, and liver were also significantly 
reduced using extracorporeal bacterial separation, thereby reducing total sepsis duration. This 
was a significant finding because duration of sepsis is directly correlated to patient outcome. 
Therefore, this work established the potential effectiveness of engineering-based bacterial 
separation devices for the treatment of sepsis through effective pathogen eradication. The 
engineering-based model described in Chapter III enabled quantitative identification of the 
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characteristics required of an extracorporeal bacteria separation device to provide biological 
benefit.  
Using the modeled described in Chapter III, I also evaluated nanoparticle-bacteria capture 
processes in blood by introducing empirical constants that mimic the interfering effects of 
biological components, which lower complexation efficacy of bacteria-nanoparticles. 
Nanoparticles with 25 nm radii were mathematically predicted to exhibit maximum capture of 
bacteria in blood due to their high mobility and large surface area to volume ratio, as compared 
to larger nanoparticles. These results were validated by previously published experimental data26. 
Unfortunately, nanoparticles of approximately 25 nm radii do not possess the magnetophoretic 
properties required to be extracted from flowing fluids even by the most advanced magnetic 
separation systems. Larger magnetic nanoparticles (> 500 nm radius) can be magnetically 
separated from flowing fluids effectively, but these larger particles do not meet the mobility and 
surface area to volume ratio requirements that enable rapid pathogen complexation and 
subsequent extraction from blood. Therefore, at this stage in my work I moved towards developing 
a colistin functionalized bacterial separation platform that did not utilize magnetic nanoparticles 
due to inherit magnetophoresis-associated downfalls. This subset of my work highlights the need 
for implementation of engineering-based principals for the elucidation of disease progression, 
specifically sepsis, to better develop treatment modalities.   
Chapter IV described my development of a mathematical model-based, colistin 
functionalized fluidic platform for A. baumannii capture and removal from fluids (Chapter IV). This 
subset of my work will be submitted for publication during February of 2017. Chapter IV 
successfully demonstrated for the first time that a novel double spiral fluidic device can be 
designed for separation and capture of A. baumannii and other bacterial cells. Hydrodynamic, 
size-based separation principles characteristic of spiral fluidics were used to inertially focus 
bacteria into equilibrium positions within the fluidic device, which has never been previously 
accomplished. In addition, the fluidic device was functionalized with a bacterial- and endotoxin-
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targeting colistin ligand in a way that allowed for capture of the inertially focused targets. This 
work successfully demonstrated the capture of Gram-negative pathogens and endotoxin using 
the colistin functionalized fluidic platform. The design of the double spiral spatially isolated the 
formed elements of the blood from the regions where bacterial binding occurs and is hypothesized 
to be responsible for bacterial capture efficiency that is not reduced in the presence of blood. The 
bacterial load captured by the compact, inertial-based microfluidic device exceeded the maximal 
bacterial load in septic patients by more than two orders of magnitude. The design parameters of 
the fluidic device enabling rapid and effective bacterial capture were informed by the previously 
described mathematical model of sepsis (Chapter III), highlighting the need for application of 
engineering-based models to better assess disease progression and treatment. The simplicity 
and robustness of this design supports the translational potential of the approach.  This approach 
breaks the paradigm of current sepsis treatment protocols by rapidly eliminating the infectious 
agents, including multi-drug resistant variants, that lead to sepsis and sepsis progression – rather 
than applying non-specific and/or ineffective systemic antibiotic treatment.  
More work must be done to continue the development of this promising technology. Next 
steps include: (1) further development of the fluidic platform for inertial focusing and separation 
of pathogens from blood cells under flow conditions suitable for rodents and scalable for larger 
animal models, (2) functionalization of the device channel walls with ligands designed to capture 
Gram-positive bacteria, in addition to Gram-negative pathogens and endotoxin, (3) evaluation of 
the molecular, cellular and systemic consequences of bacterial and endotoxin removal from the 
circulation of septic animal models, and (4) further escalation of the technology for clinical 
translation.  
The technology developed through this work has the potential to serve as a novel blood 
cleansing therapeutic for the treatment of human disease. Inertial-based fluidic platforms hold 
many advantages over membrane-based blood cleansing filter devices in terms of effectiveness 
and hemocompatibility. The scalable fluidic platform highlighted by this dissertation is capable of 
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removing pathogens and endotoxins from circulating fluids, whereas competing technologies 
cannot. This design has the capacity to meet the current unmet need of sepsis while also 
bolstering inertial-based fluidic use and accelerating scientific advancement. This 
hemocompatible, blood purification technology has the potential to protect and preserve lives in 
the face of a number of growing health concerns, including the rise of sepsis and multi-drug 
resistant bacterial infections. 
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APPENDIX 
 
A. CHAPTER III SUPPLEMENTARY MATERIAL 
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Table A1. Bacterial burden experienced by immunocompromised K. pneumoniae rodent model 
administered antibiotic. 
  
 137 
 
Table A2. 100% efficient bacterial separation accelerates K. pneumoniae clearance (≤1 CFU/mL) 
in immunocompromised rodent model. 
  
 138 
 
Table A3. Bacteria separation in immunocompromised K. pneumoniae rodent model reduced 
bacterial burden experienced. 
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Table A4. K. pneumoniae clearance (≤1 CFU/mL) in immunocompromised rodent model 
accelerated with improved bacterial separation efficiencies. 
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Table A5. 60% or greater bacteria separation efficiencies reduced bacterial burden in K. 
pneumoniae immunocompromised rodent model. 
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Figure A1. Bacterial burden increased over time in neutropenic rodents until reaching a lethal K. 
pneumoniae concentration. The median numbers of bacteria in each compartment observed 
experimentally in previous literature were used as the initial conditions for these simulations98,101, 
and trajectories were generated using the parameter estimates described in the Materials and 
Methods of Chapter III. 
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Figure A2. K. pneumoniae bacterial burden trajectories post inoculation in immunocompromised 
rodents treated with colistin sulfate (3 mg/kg).  
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Figure A3. K. pneumoniae burden decreased more rapidly with bacterial separation treatment in 
combination with antibiotic. 100% bacterial separation efficiency, combined with antibiotic 
administration (colistin methanosulfate, 3mg/kg), resulted in bacterial clearance from the blood 
compartment in 32 h. This was 29 h faster than antibiotic treatment alone. 
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Figure A4. 100% and 60% bacterial separation efficiencies had a significant impact on overall 
bacterial clearance rates from the blood compartment of immunocompromised K. pneumoniae 
rodent model. 20% bacterial separation efficiency was not efficient enough to significantly impact 
the overall bacterial clearance rate and resulted in the same clearance rates as antibiotic 
treatment alone. 
 
 145 
 
Figure A5. Net bacterial growth rates estimated by linearization of experimental data. The net 
bacterial growth rate of A. baumannii in the liver of a non-immunocompromised rodent model is 
provided as an example calculation96.  
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B. CHAPTER IV SUPPLEMENTARY MATERIAL 
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Table B1. Colistin resistance. Minimum inhibitory concentrations (MICs; µg/ml) of colistin-
resistant A. baumannii isolates. Results are listed as the mean ± SD, n = 3. 
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Table B2. Blood cell counts of whole, human blood before and after passage through 
functionalized microfluidic devices. Red blood cell counts, white blood cell counts, and platelet 
counts of blood flowed through colistinated and PEGylated double spiral fluidic devices at 0.2 mL 
min-1 were not significantly different than the control group. Unaltered blood not passed through 
a microfluidic device was used as the control. Data were compared using one-way ANOVA 
followed by post hoc Tukey’s multiple comparison test. Results are listed as the mean ± SD, n = 3. 
*P < 0.01, **P < 0.001, ***P < 0.0001. 
  
 149 
	
Table B3. Summary of hemolysis levels of whole, human blood flowed through functionalized 
microfluidic devices. Whole, human blood was flowed through the colistinated and PEGylated 
double spiral microfluidic devices. Blood passage through the devices did not cause hemolysis. 
Blood containing Triton-X (20 v/v %) was used as a positive control. The negative control was 
blood that was not passed through a double spiral fluidic device. Data were compared using one-
way ANOVA followed by post hoc Tukey’s multiple comparison test. Results are listed as the 
mean ± SD, n = 5. *P < 0.01, **P < 0.001, ***P < 0.0001. 
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Figure B1. Schematic description of colistin immobilization onto the microchannel walls. NHS 
was used to couple Silane-PEG-NHS to one of the five similarly reactive L-α-diaminobutyric acid 
(Dab) residues of colistin through the amine side chain of Dab59. The NHS group of Silane-PEG-
NHS covalently binds to any single, comparably reactive amine residue of the colistin antibiotic 
via carbodiimide chemistry, resulting in Colistin-PEG-Silane60,61. The silane end of Colistin-PEG-
Silane forms siloxane bonds to the PDMS-based channel walls, resulting in colistin being 
extended into the lumen of the channel.  
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Figure B2. Confirmation of colistin decoration within microchannel. a, Fluorescent labeling of the 
amine groups of colistin was carried out with ATTO 488 NHS ester dye. The ATTO 488 NHS ester 
dye was added to a colistinated device and then washed with PBS. Staining indicates the 
presence of colistin within the microchannel. b, Standard dilutions of ATTO 488 NHS ester in 
DMSO were used to generate a standard fluorescence curve. c, Fluorescence generated from 
ATTO 488 NHS ester stained colistinated device and ATTO 488 NHS ester PEGylated device 
were compared to the standard curve. It was determined that 1.76 µg of colistin are present within 
the colistinated double spiral device. Results are plotted as the mean ± SD, n = 3. 
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Figure B3. Colistin ligand retention within the double spiral microchannel. The release of colistin 
from the colistinated device was analyzed using a colistin ELISA (Bioo Scientific). PBS buffer was 
continuously flowed through a colistinated microfluidic device at 0.2 mL min-1. The fluid was 
captured from the outlet at the time points indicated to analyze the possible detachment of colistin 
from the channel walls. Under continuous flow, 300 ng of colistin were released from the channel 
over the course of 2 hours. These levels of colistin are non-toxic. Importantly, no colistin was 
detectable in the outlet flow after approximately 40 minutes, making feasible a wash to remove 
uncoupled colistin from the device before use. Results are plotted as the mean ± SD, n = 3. 
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Figure B4. Evaluation of Gram-positive bacterial capture. Pathogen capture capacity of Gram-
positive B. subtilis 1A578 when spiked into PBS and flowed through the colistinated and 
PEGylated double spiral microfluidic devices at 0.2 ml min−1. The lack of capture indicates the 
specificity of colistin for Gram-negative pathogens. Results are plotted as the mean ± SD, n = 3. 
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Figure B5. Quantification of endotoxin capture capacity. Endotoxin was spiked into endotoxin-
free water (1 EU ml−1) and flowed through the colistinated and PEGylated double spiral 
microfluidic devices at 0.2 ml min−1. The amount of endotoxin captured over time was assessed. 
Results are plotted as the mean ± SD, n = 3. 
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